propranolol has been researched along with Hypertension, Portal in 328 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 9.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| "Damping index of the HV waveform by Doppler ultrasonography might be a non-invasive supplementary tool in evaluating the severity of portal hypertension and in responding to propranolol in patients with liver cirrhosis." | 9.12 | Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. ( Baik, SK; Chang, SJ; Kim, HS; Kim, JW; Kim, MY; Kim, YJ; Kwon, SO; Lee, SS; Lim, DW; Park, DH, 2007) |
| "In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by > or =25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months." | 9.11 | Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. ( Gornbein, J; Han, SH; Jensen, DM; Jutabha, R; Martin, P; Savides, T, 2005) |
| "Propranolol ameliorates thrombocytopenia in patients with cirrhosis." | 9.10 | Propranolol ameliorates thrombocytopenia in patients with cirrhosis. ( Iwao, T; Oho, K; Sakai, K; Sata, M; Toyonaga, A, 2002) |
| "To investigate the stereoselective metabolism of the propranolol enantiomers and its impact on portal haemodynamics in patients with liver cirrhosis since only S-propranolol is haemodynamically active." | 9.09 | Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. ( Brensing, K; Hoppe, A; Paar, D; Potyka, U; Raab, P; Sauerbruch, T; Schepke, M, 1999) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 9.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 9.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "This study tested the hypothesis that reduction in the hyperdynamic systemic circulation with propranolol in patients with alcoholic cirrhosis and distal splenorenal shunt would lead to improved maintenance of portal perfusion." | 9.07 | The effect of propranolol on portal perfusion in patients with alcoholic cirrhosis having distal splenorenal shunt. ( Galloway, JR; Gilmore, GT; Henderson, JM; Mackay, G, 1994) |
| "The aim of this study was to investigate the effect of rectal ozone on portal vein oxygenation and the pharmacokinetic changes of propranolol in patients with liver cirrhosis." | 7.77 | The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study). ( Fouad, EA; Kotb, HI; Zaky, S, 2011) |
| " This study was conducted to investigate any protective effect of early propranolol administration in the development and degree of esophageal varices in cirrhotic rats with portal hypertension." | 7.75 | Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats. ( Alatsakis, M; Ballas, KD; Marakis, GN; Pavlidis, TE; Psarras, K; Rafailidis, S; Sakantamis, AK; Tzioufa-Asimakopoulou, V, 2009) |
| "In this model, pretreatment with propranolol prevented the increase in portal venous inflow, which occurs following hemorrhage and volume restitution with Haemaccel." | 7.71 | Systemic and splanchnic hemodynamics following hemorrhage and volume restitution with Haemaccel in portal hypertensive rats: the effect of propranolol. ( Arish, A; Hilzenrat, N; Sikuler, E; Yaari, A, 2001) |
| " Seven patients with alcoholic cirrhosis received verapamil, 10 mg i." | 7.67 | Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. ( Cerini, R; Hadengue, A; Koshy, A; Lebrec, D; Lee, SS; Moreau, R, 1989) |
| "The effect of long-term propranolol administration on esophageal varices, portocollateral shunting, portal pressure, hepatosplanchnic hemodynamics, and liver function was studied in a pig model with experimentally induced prehepatic portal hypertension and esophageal varices." | 7.67 | Endoscopic, portographic, and hemodynamic evaluation of prolonged propranolol administration in pigs with experimental portal hypertension and esophageal varices. ( Jensen, LS; Juhl, CO; Krarup, N; Larsen, JA; Nielsen, TH, 1989) |
| "Propranolol (20 mg 4 times a day) was given to patients with liver cirrhosis or fatty infiltration of the liver." | 7.66 | Propranolol increases arterial ammonia in liver cirrhosis. ( Koorevaar, G; Silberbusch, J; van Buuren, HR; van der Velden, PC, 1982) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Tertatolol was rapidly absorbed with a Cmax of 70 +/- 51 micrograms/l at a peak time of 0." | 6.67 | Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ( Brouard, R; Caillau, H; Calès, P; Crambes, O; Desmorat, H; Jung, L; Pascal, JP; Rocher, I; Urien, S; Vinel, JP, 1993) |
| "No significant changes in the size of esophageal varices were observed after propranolol or placebo administration." | 6.67 | Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. ( Bordas, JM; Bosch, J; Feu, F; Garcia-Pagán, JC; Rodés, J, 1991) |
| "When propranolol was administered to patients with alcoholic cirrhosis and marginal liver function, as reflected by ammonia levels above 60 microM, it caused a significant increase in ammonia levels in arterialized-venous and arterial, but not in venous, blood (p less than 0." | 6.66 | Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol. ( Lieber, CS; Snady, H, 1988) |
| "Cirrhosis recurrence is frequent after orthotopic liver transplantation for hepatitis C virus (HCV)." | 5.39 | Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. ( Abraldes, JG; Berzigotti, A; Bosch, J; Carrión, JA; Forns, X; García-Pagán, JC; García-Valdecasas, JC; Navasa, M; Schepis, F; Vukotic, R, 2013) |
| " A total of 94 cirrhotic patients having large oesophageal varices without history of variceal bleeding were randomized to three treatment groups and given 2 months' treatment with propranolol plus placebo, propranolol plus antibiotics (norfloxacin 400 mg BD) or propranolol plus probiotic (VSL#3, 900 billion/day) randomly assigned in 1:1:1 ratio." | 5.17 | Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. ( Garg, V; Gupta, N; Kumar, A; Sarin, SK; Sharma, BC; Sharma, P, 2013) |
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 5.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| "Damping index of the HV waveform by Doppler ultrasonography might be a non-invasive supplementary tool in evaluating the severity of portal hypertension and in responding to propranolol in patients with liver cirrhosis." | 5.12 | Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. ( Baik, SK; Chang, SJ; Kim, HS; Kim, JW; Kim, MY; Kim, YJ; Kwon, SO; Lee, SS; Lim, DW; Park, DH, 2007) |
| "In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by > or =25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months." | 5.11 | Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. ( Gornbein, J; Han, SH; Jensen, DM; Jutabha, R; Martin, P; Savides, T, 2005) |
| "Sixty patients with cirrhosis and oesophageal varices with no history but at high risk of bleeding were randomized to ligation treatment (30 patients) or propranolol (30 patients)." | 5.11 | Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. ( Elefsiniotis, I; Galanis, P; Goulas, S; Liatsos, C; Mavrogiannis, C; Papanikolaou, IS; Psilopoulos, D; Sparos, L, 2005) |
| " The aim of our study was to find out if propranolol can prevent the bleeding from esophageal varices and if it acts by reducing the portal inflow due to splanchnic vasodilatation." | 5.10 | Long term effects of propranolol on portal pressure in cirrhotic patients. ( Orban-Schiopu, AM; Popescu, CR, 2003) |
| "To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulated hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis." | 5.10 | Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. ( Koch, L; Layer, G; Sauerbruch, T; Schiedermaier, P; Stoffel-Wagner, B, 2003) |
| "Propranolol ameliorates thrombocytopenia in patients with cirrhosis." | 5.10 | Propranolol ameliorates thrombocytopenia in patients with cirrhosis. ( Iwao, T; Oho, K; Sakai, K; Sata, M; Toyonaga, A, 2002) |
| "We compared propranolol therapy and endoscopic ligation for the primary prevention of bleeding from esophageal varices." | 5.09 | Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. ( Kumar, M; Lamba, GS; Misra, A; Murthy, NS; Sarin, SK, 1999) |
| "Thirty cirrhotic patients with PHT, grade III to IV oesophageal varices, hepatic venous pressure gradient > or = 12 mmHg and no prior history of upper gastrointestinal bleeding were randomized to receive propranolol (to reduce their pulse rate by 25% from baseline, n = 15) and EVL (weekly to fortnightly until variceal eradication, n = 15)." | 5.09 | Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. ( Biswas, PK; Das, T; De, BK; Ghoshal, UC; Santra, A, 1999) |
| "To investigate the stereoselective metabolism of the propranolol enantiomers and its impact on portal haemodynamics in patients with liver cirrhosis since only S-propranolol is haemodynamically active." | 5.09 | Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. ( Brensing, K; Hoppe, A; Paar, D; Potyka, U; Raab, P; Sauerbruch, T; Schepke, M, 1999) |
| "Band ligation of esophageal varices may accentuate gastropathy, which in this study was partly relieved by propranolol." | 5.09 | The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. ( Chen, TA; Cheng, JS; Chiang, HT; Hsu, PI; Lai, KH; Lin, CK; Lo, GH; Wang, EM, 2001) |
| "The absence of any effects on the parameters of portal haemodynamics would appear to deny clonidine any significant role in preventing first bleeding resulting from the rupture of oesophageal varices." | 5.08 | Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. ( Cioni, G; Cristani, A; D'Alimonte, P; Romagnoli, R; Tincani, E; Turrini, F; Ventura, E, 1995) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 5.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 5.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "This study tested the hypothesis that reduction in the hyperdynamic systemic circulation with propranolol in patients with alcoholic cirrhosis and distal splenorenal shunt would lead to improved maintenance of portal perfusion." | 5.07 | The effect of propranolol on portal perfusion in patients with alcoholic cirrhosis having distal splenorenal shunt. ( Galloway, JR; Gilmore, GT; Henderson, JM; Mackay, G, 1994) |
| "A prospective randomized double-blind study was conducted to evaluate the efficacy of propranolol in patients with portal hypertension undergoing long-term endoscopic sclerotherapy (EST) for recurrent variceal bleeding." | 5.07 | A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. ( Acharya, SK; Dasarathy, S; Pande, JN; Saksena, S, 1993) |
| "Detailed examination of hemodynamics in patients with portal and pulmonary hypertension was performed upon acute drug tests and course administration of nitrosorbide++, corinfar and propranolol." | 5.07 | [Drug therapy of pulmonary and portal hypertension in liver cirrhosis]. ( Andreev, NG; Maev, IV; Vorob'ev, LP, 1991) |
| "To study the polymorphic markers CYP2D6*4 (G1846A, rs3892097), CYP2D6*6 (T1707del, rs5030655), CYP2D6*10 (C100T, rs1065852), CYP2D6*41 (G2988A, rs28371725) and CYP2D6*3 (A2549del, rs4986774) role in treatment optimization of portal hypertension with propranolol in patients with liver cirrhosis (LC)." | 4.12 | [CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis]. ( Akmalova, KA; Denisenko, NP; Loranskaya, ID; Parusov, AI; Sozaeva, ZA; Sychev, DA; Turkina, OL; Zastrozhin, MS, 2022) |
| "0 years, 34 boys) with CLD who needed liver biopsy but could not be done due to hypersplenism-related thrombocytopenia (platelets <100,000/mm(3) and/or total leukocyte counts <4,000/mm(3) with splenomegaly) were recruited and given a 4-week trial of long-acting propranolol (1." | 3.81 | β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children. ( Agarwal, J; Baijal, SS; Kumar, S; Poddar, U; Shava, U; Srivastava, A; Yachha, SK, 2015) |
| "The aim of this study was to describe the results of endoscopic secondary prophylaxis, alone or in combination with propranolol, used to prevent upper gastrointestinal bleeding (UGIB) in children and adolescents with esophageal varices." | 3.79 | Endoscopic and pharmacological secondary prophylaxis in children and adolescents with esophageal varices. ( Bittencourt, PF; Carvalho, SD; dos Santos, JM; Fagundes, ED; Ferreira, AP; Ferreira, AR; Ferreira, LS; Figueiredo Filho, PP; Magalhães, MC; Penna, FJ, 2013) |
| "Droxidopa might be an effective therapeutic agent for hemodynamic and renal alterations of liver cirrhosis and should be tested in cirrhosis patients." | 3.78 | Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. ( Augustin, S; Brull, A; Coll, M; Esteban, R; Ezkurdia, N; Genescà, J; Guardia, J; Martell, M; Raurell, I; Rodriguez, S, 2012) |
| "The aim of this study was to investigate the effect of rectal ozone on portal vein oxygenation and the pharmacokinetic changes of propranolol in patients with liver cirrhosis." | 3.77 | The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study). ( Fouad, EA; Kotb, HI; Zaky, S, 2011) |
| "Propranolol treatment has been used to prevent variceal bleeding; however, controlled trials of its effectiveness have produced conflicting results." | 3.76 | Drug therapy for portal hypertension. ( Rector, WG, 1986) |
| " This study was conducted to investigate any protective effect of early propranolol administration in the development and degree of esophageal varices in cirrhotic rats with portal hypertension." | 3.75 | Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats. ( Alatsakis, M; Ballas, KD; Marakis, GN; Pavlidis, TE; Psarras, K; Rafailidis, S; Sakantamis, AK; Tzioufa-Asimakopoulou, V, 2009) |
| " propranolol before initiating secondary prophylaxis for variceal bleeding is a useful tool in predicting the efficacy of non-selective beta-blockers." | 3.75 | Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. ( Abraldes, JG; Berzigotti, A; Bosch, J; García-Pagán, JC; La Mura, V; Raffa, S; Retto, O, 2009) |
| "propranolol, has been shown to be effective in compensated patients with alcoholic cirrhosis." | 3.75 | [Pharmacological therapy of portal hypertension]. ( Miotti, T; Reichen, J, 1985) |
| "In this model, pretreatment with propranolol prevented the increase in portal venous inflow, which occurs following hemorrhage and volume restitution with Haemaccel." | 3.71 | Systemic and splanchnic hemodynamics following hemorrhage and volume restitution with Haemaccel in portal hypertensive rats: the effect of propranolol. ( Arish, A; Hilzenrat, N; Sikuler, E; Yaari, A, 2001) |
| "Propranolol can reduce portal hypertension, therefore is recommended in prevention of variceal bleeding in patients with liver cirrhosis." | 3.69 | [Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II]. ( Bołdys, H; Hartleb, M; Nowak, A; Nowak, S; Rudzki, K, 1994) |
| "This study evaluates systemic and splanchnic haemodynamics and the effect of propranolol in 15 patients with presinusoidal portal hypertension (portal vein obstruction, n = 11; schistosomiasis, n = 4)." | 3.67 | Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol. ( Braillon, A; Hadengue, A; Lebrec, D; Moreau, R; Roulot, D; Sayegh, R, 1989) |
| " Seven patients with alcoholic cirrhosis received verapamil, 10 mg i." | 3.67 | Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. ( Cerini, R; Hadengue, A; Koshy, A; Lebrec, D; Lee, SS; Moreau, R, 1989) |
| "The effect of long-term propranolol administration on esophageal varices, portocollateral shunting, portal pressure, hepatosplanchnic hemodynamics, and liver function was studied in a pig model with experimentally induced prehepatic portal hypertension and esophageal varices." | 3.67 | Endoscopic, portographic, and hemodynamic evaluation of prolonged propranolol administration in pigs with experimental portal hypertension and esophageal varices. ( Jensen, LS; Juhl, CO; Krarup, N; Larsen, JA; Nielsen, TH, 1989) |
| "To elucidate the mechanism by which propranolol reportedly affects portal hemodynamics, we investigated the effect of propranolol on systemic and splanchnic hemodynamics in 15 patients with portal hypertension and esophageal varices by simultaneous catheterization of the portal vein and the right hepatic vein and measurement of portal venous flow using an ultrasound doppler system." | 3.67 | Effects of propranolol on portal hemodynamics in patients with chronic liver disease. ( Hatano, H; Koen, H; Nakayama, T; Nomura, F; Ohnishi, K; Saito, M; Sugita, S; Terabayashi, H; Tsukamoto, T; Wada, K, 1985) |
| "Propranolol (20 mg 4 times a day) was given to patients with liver cirrhosis or fatty infiltration of the liver." | 3.66 | Propranolol increases arterial ammonia in liver cirrhosis. ( Koorevaar, G; Silberbusch, J; van Buuren, HR; van der Velden, PC, 1982) |
| " The aim of this study was to evaluate the effects of 5-MTHF in combination with propranolol on HVPG and nitric oxide bioavailability markers in patients with cirrhosis and portal hypertension." | 3.30 | 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. ( Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol is a non-selective β-blocker with intrinsic anti-α(1)-adrenergic activity, potentially more effective than propranolol in reducing hepatic venous pressure gradient (HVPG)." | 2.77 | Carvedilol or propranolol in portal hypertension? A randomized comparison. ( Bendtsen, F; Feldager Hansen, E; Grønbæk, H; Hobolth, L; Møller, S; Roelsgaard, K, 2012) |
| "Primary end points were recurrence of variceal bleeding or death." | 2.75 | Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. ( Agrawal, A; Gupta, N; Jha, SK; Kumar, A; Mishra, SR; Sarin, SK; Sharma, BC, 2010) |
| " Additionally, they randomly received either placebo (N = 15) or irbesartan (step-up dosage titration up to 300 mg/d, N = 17)." | 2.73 | Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. ( Flacke, S; Ghauri, M; Heller, J; Herold, T; Sauerbruch, T; Schepke, M; Stoffel-Wagner, B; Wiest, R, 2008) |
| "Propranolol is a widely used drug for prophylaxis of variceal bleeding in patients with cirrhosis, but not all patients show an adequate clinical response." | 2.72 | Functional status of beta-2-adrenoceptor in isolated membranes of mature erythrocytes from patients with cirrhosis and oesophageal varices. ( De-Madaria, E; Hernández, FT; Horga, JF; Irurzun, J; Palazón, JM; Pascual, S; Perez-Mateo, M; Such, J; Zapater, P, 2006) |
| "Carvedilol is a nonselective beta-blocker with alpha(1)-adrenergic blocking activity." | 2.71 | Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. ( Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Yang, YY, 2004) |
| "Short-term carvedilol administration is more powerful than propranolol in decreasing hepatic venous pressure gradient (HVPG) in cirrhotic patients, but induces arterial hypotension that may prevent its long-term use in portal hypertensive patients." | 2.70 | Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. ( Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; De Diego, A; García-Pagán, JC; Lampreave, JL; Matilla, A; Moitinho, E; Piera, C, 2002) |
| "Carvedilol is a relatively safe, effective portal hypotensive agent, both acutely and over 7 days, but not superior to propranolol, at least in Indians." | 2.70 | Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. ( Biswas, PK; Das, D; De, BK; Maity, AK; Majumdar, D; Mandal, SK; Sen, S, 2002) |
| "Propranolol plus prazosin has a greater portal pressure-lowering effect than propranolol plus ISMN." | 2.69 | Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. ( Albillos, A; Bandi, JC; Bosch, J; Cacho, G; Calleja, JL; Escartín, P; Escorsell, A; García-Pagán, JC; Iborra, J; Pérez-Paramo, M, 1998) |
| "Propranolol was well tolerated with minimal side effects in our patients with portal hypertension." | 2.69 | Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study. ( Grand, RJ; Langhans, N; Shashidhar, H, 1999) |
| "Tertatolol was rapidly absorbed with a Cmax of 70 +/- 51 micrograms/l at a peak time of 0." | 2.67 | Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ( Brouard, R; Caillau, H; Calès, P; Crambes, O; Desmorat, H; Jung, L; Pascal, JP; Rocher, I; Urien, S; Vinel, JP, 1993) |
| "Eighteen cirrhotic patients with esophageal varices at risk for bleeding took part in a double-blind study." | 2.67 | Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics. ( Abbati, G; Cioni, G; Cristani, A; D'Alimonte, P; Romagnoli, R; Tincani, E; Ventura, E; Ventura, P; Vignoli, A, 1993) |
| "When molsidomine was added, TAV was further decreased (-17." | 2.67 | [Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound]. ( Blanc, F; Bruel, JM; Ciurana, AJ; Le Quellec, A; Michel, H; Monnin, JL; Pascal, JP; Taourel, P; Vinel, JP, 1992) |
| "Propranolol-treated patients had fewer episodes of acute bleeding than controls (0." | 2.67 | Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. ( Bosch, J; González, A; Panés, J; Pérez, R; Pérez-Ayuso, RM; Piqué, JM; Quintero, E; Rigau, J; Valderrama, R; Viver, J, 1991) |
| " Daily dosage was determined by the administration of progressively increasing doses of propranolol with the hepatic vein catheter in place to achieve a 25% decrease in hepatic venous pressure gradient, a decrease in hepatic venous pressure gradient to less than 12 mm Hg or a decrease in resting heart rate to less than 55 beats/min." | 2.67 | Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. ( Bosch, J; Conn, HO; Fisher, RL; Garcia-Tsao, G; Grace, ND; Groszmann, RJ; Matloff, DS; Navasa, M; Rodés, J; Wright, SC, 1991) |
| "No significant changes in the size of esophageal varices were observed after propranolol or placebo administration." | 2.67 | Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. ( Bordas, JM; Bosch, J; Feu, F; Garcia-Pagán, JC; Rodés, J, 1991) |
| " The Cmax was significantly higher with C propranolol in both phases." | 2.66 | Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. ( Blanc, M; Calès, P; Cotonat, J; Grasset, D; Meskens, C; Pascal, JP; Ravaud, A; Vinel, JP, 1989) |
| "Propranolol is a useful medicament for the reduction of esophagic varices size and prevention of digestive bleeding in cirrhotic patients." | 2.66 | [Propranolol in the prevention of digestive bleeding in cirrhotic patients]. ( Castro, R; Glez Cansino, J; Sotto, A, 1989) |
| "When propranolol was administered to patients with alcoholic cirrhosis and marginal liver function, as reflected by ammonia levels above 60 microM, it caused a significant increase in ammonia levels in arterialized-venous and arterial, but not in venous, blood (p less than 0." | 2.66 | Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol. ( Lieber, CS; Snady, H, 1988) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Carvedilol is a nonselective beta-blocker with a mild anti-alfa-1-adrenergic activity." | 2.50 | Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. ( D'Amico, G; D'Amico, M; Perricone, G; Sinagra, E; Tinè, F, 2014) |
| "Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade." | 2.46 | The role of carvedilol in the management of portal hypertension. ( Hayes, PC; Tripathi, D, 2010) |
| "Carvedilol appears to be a potentially viable option for treating portal hypertension." | 2.42 | Evaluation of carvedilol for the treatment of portal hypertension. ( Hemstreet, BA, 2004) |
| "Terlipressin has longer effects and is more effective and safer than vasopressin alone or in combination with nitroglycerin." | 2.41 | The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. ( Bosch, J, 2000) |
| "Hemorrhage from esophageal varices is a life-threatening event in patients with liver cirrhosis." | 2.39 | Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature. ( Gross, M; Zoller, WG, 1996) |
| "Spironolactone, which has been shown to lower HVPG in patients with cirrhosis, produces a reduction in plasma volume that attenuates the increased cardiac output associated with cirrhosis and triggers vasoactive mechanisms that decrease splanchnic blood flow." | 2.38 | New approaches in the pharmacologic treatment of portal hypertension. ( Bosch, J; Fernández, M; Feu, F; García-Pagán, JC; Luca, A; Pizcueta, P; Rodés, J, 1993) |
| "The best results obtained in treatment of portal hypertension were: esophagogastric devascularization and splenectomy (EGDS), although risk of rebleeding persists; classical (proximal) splenorenal shunt (SRS) should be abandoned; distal splenorenal shunt may complicate with hepatic encephalopathy, although later and in a lower percentage than in SRS." | 2.38 | Portal hypertension in schistosomiasis: pathophysiology and treatment. ( Da Silva, LC, 1992) |
| "Although pharmacologic treatment of portal hypertension is known to be efficient, there are advances still to be made." | 2.38 | Current status and future goals of the pharmacologic reduction of portal hypertension. ( Lebrec, D, 1990) |
| "Only about one third of patients with esophageal varices eventually bleed." | 2.38 | [Treatment of hemorrhage of esophageal varices]. ( Sauerbruch, T, 1990) |
| "The development of bleeding esophagogastric varices and the methods used to treat this complication are all unsatisfactory either in the short or long term." | 2.37 | Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis. ( Bizer, LS, 1984) |
| "Bleeding from esophageal varices remains a difficult clinical problem, carrying a high likelihood both of rebleeding and of mortality." | 2.37 | Management of the patient with hemorrhaging esophageal varices. ( Cello, JP; Crass, RA; Grendell, JH; Trunkey, DD, 1986) |
| "Peptic ulcer disease, oesophageal varices and Mallory-Weiss tear are the major causes." | 2.36 | Management of upper gastrointestinal haemorrhage. ( Korman, MG, 1983) |
| "Her pregnancy was uneventful until 31 weeks gestation when she presented with dyspnoea." | 1.48 | Pregnancy in a patient with portal hypertension secondary to liver cirrhosis. ( Lelei-Mailu, FJ; Mariara, CM, 2018) |
| "Propranolol is a non-selective β-blocker that is recommended for the treatment of PH." | 1.42 | Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats. ( Hsieh, YC; Lee, KC; Lee, PC; Lee, TY; Lee, WP; Lin, HC; Yang, YY, 2015) |
| "Propranolol was associated with reduction in bleeding episodes (P < 0." | 1.42 | Extrahepatic portal vein obstruction in Egyptian children. ( El-Karaksy, HM; El-Koofy, N; El-Shabrawi, M; Helmy, H; Mohsen, N; Nabil, N, 2015) |
| "Metformin-treated CCl4-cirrhotic rats had lower PP and hepatic vascular resistance than vehicle-treated rats, without significant changes in MAP or PBF." | 1.42 | Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. ( Bosch, J; Erice, E; García-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Lafoz, E; Sarin, SK; Tripathi, DM, 2015) |
| "Cirrhosis recurrence is frequent after orthotopic liver transplantation for hepatitis C virus (HCV)." | 1.39 | Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. ( Abraldes, JG; Berzigotti, A; Bosch, J; Carrión, JA; Forns, X; García-Pagán, JC; García-Valdecasas, JC; Navasa, M; Schepis, F; Vukotic, R, 2013) |
| "Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence." | 1.38 | An unusual cause of delayed puberty: Berardinelli- Seip syndrome. ( Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V, 2012) |
| "Portal hypertension was induced by PVL (portal vein ligation) in Sprague-Dawley rats." | 1.37 | Propranolol modulates the collateral vascular responsiveness to vasopressin via a G(α)-mediated pathway in portal hypertensive rats. ( Chang, CC; Chuang, CL; Huang, HC; Huo, TI; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Wang, SS, 2011) |
| "Propranolol treatment reduces MAP significantly in hypertensive patients with cirrhosis." | 1.36 | The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients. ( Jha, S; Kumar, A; Mishra, SR; Sarin, SK; Sharma, BC; Sharma, P, 2010) |
| "Portal hypertension is a hemodynamic syndrome due to pathological increase in portal flow and portal pressure." | 1.35 | Combined use of propranolol and nifedipine offers better effects on portal vein nonuniform remodeling in carbon tetrachloride (CCl(4))-induced portal hypertensive rats. ( Jiang, ZL; Qin, KR; Shi, B; Wu, GQ; Zhang, ZQ; Zhu, L, 2009) |
| "All of them had high-risk esophageal varices at endoscopy." | 1.35 | Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. ( Bittencourt, PL; Carrilho, FJ; da Rocha, EC; Dos Santos Bomfim, V; Farias, AQ; Kassab, F; Vezozzo, DC, 2009) |
| "Successful pharmacological treatment of portal hypertension can prevent the risk of the variceal bleeding, and contribute to reduce the morbidity and mortality in patients with liver cirrhosis." | 1.33 | [Pharmacological therapy of portal hypertension--focused on Korean data]. ( Baik, SK, 2005) |
| "Such varices are often the source of difficult-to-treat recurrent or chronic bleeding." | 1.33 | Chronic stomal variceal bleeding after colonic surgery in patients with portal hypertension: efficacy of beta-blocking agents? ( Detry, RJ; Douala, HC; Druez, PM; Geubel, AP; Kartheuser, AH; Kartheuzer, AH; Noubibou, M, 2006) |
| "The variceal recurrence rate was 65 and 38." | 1.32 | Long-term outcome after sclerotherapy with or without a beta-blocker for variceal bleeding in children. ( Elkabes, B; Saner, G; Sökücü, S; Süoglu, OD, 2003) |
| "Ectopic intestinal varices are rarely responsible for lower gastrointestinal (GI) haemorrhage." | 1.32 | Ectopic intestinal varices as a rare cause of lower gastrointestinal haemorrhage. ( Ahmed, I; Alam, A; Alvi, A; Butt, AK; Khan, AA; Niazi, A; Sarwar, S; Shafqat, F; Tarique, S, 2003) |
| "Larger gastric varices have been shown to be the only risk factor for rebleeding (adjusted odds ratio, 4." | 1.31 | Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis. ( Chen, GH; Wu, CY; Yeh, HZ, 2002) |
| "Propranolol or atenolol was administered by gavage in portal vein-stenosed and sham-operated rats." | 1.31 | Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. ( Chagneau, C; Heller, J; Lebrec, D; Moreau, R; Pateron, D; Philippe, M; Poirel, O; Sogni, P; Tazi, KA, 2000) |
| " It was decided that patients whose portal pressure was reduced by 30% with the use of the drug would not undergo surgery and that treatment would consist of the chronic use of propranolol, associated with sclerosis of esophageal varices." | 1.30 | Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. ( Alfieri, F; Baía, CE; Beer, A; Mies, S; Neto, OB; Pereira, LM; Raia, S; Sette, MJ, 1997) |
| " Our aim was to study the hemodynamic effects of the early and chronic administration of PR and spironolactone (SPN), alone or in combination, in a model of hepatic fibrosis and sinusoidal portal hypertension induced in rats by bile duct ligation." | 1.30 | Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. ( Calès, P; Douay, O; Gallois, Y; Le Jeune, JJ; Maïga, MY; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL, 1997) |
| " The present study aimed to investigate whether chronic administration of propranolol could improve vascular responsiveness in portal hypertensive rats." | 1.30 | Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats. ( Hong, CY; Hou, MC; Huang, YT; Lin, HC; Tsai, JF, 1997) |
| "Portal hypertension was induced by partial portal vein ligation in Sprague-Dawley rats." | 1.30 | Hemodynamic effects of chronic tetrandrine and propranolol administration on portal hypertensive rats. ( Hong, CY; Huang, YT; Lin, HC; Liu, TB; Yang, MC, 1997) |
| "Propranolol or saline was administered by gavage, octreotide by subcutaneous injection." | 1.30 | Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats. ( Cheng, YR; Hong, CY; Hou, MC; Huang, YT; Lee, SD; Lin, HC, 1998) |
| "Portal hypertension was induced by partial portal vein ligation (PVL)." | 1.30 | Increased angiogenesis in portal hypertensive rats: role of nitric oxide. ( Battegay, E; Sieber, CC; Stumm, M; Sumanovski, LT; van der Kooij, M, 1999) |
| "The true form of portal hypertension is considered to be congestive gastropathy from the points that PHG is observed in high frequencies in the high portal pressure group, the severe esophageal varices group and group without gastrorenal or splenorenal shunt, that the mucosal blood flow rate in the lesion increased and that venectasia is present in the submucosal layer." | 1.29 | [Study of gastric mucosal lesion in portal hypertension]. ( Maruyama, T, 1995) |
| "Propranolol was administered orally to reduce portal hypertension, resulting in a progressive decrease in urinary microalbumin excretion." | 1.29 | IgA nephropathy associated with portal hypertension in liver cirrhosis due to non-alcoholic and non-A, non-B, non-C hepatitis. ( Aosaki, N; Hamaguchi, K; Iigaya, T; Kaneko, K; Miyoshi, Y; Monma, T; Nakamura, M; Ohishi, A; Sugiura, H; Watanabe, R, 1994) |
| " Thus, the hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, was studied in conscious and unrestrained rats in two models of portal hypertension." | 1.29 | Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension. ( Cailmail, S; Lebrec, D; Ohsuga, M, 1993) |
| "Portal hypertension is due to cirrhosis in 10 cases and to metastases to the liver in 4 cases." | 1.28 | [Colostomy-induced varices in portal hypertension]. ( Damamme, B; Poilleux, J, 1992) |
| " Nipradilol, at the dosage used in the present study, did not appear to exert a nitrovasodilating effect to enhance the portal pressure reduction induced by beta-blocking action." | 1.28 | Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. ( Aramaki, T; Katsuta, Y; Komeichi, H; Kurokawa, H; Ohsuga, M; Okumura, H; Satomura, K; Sekiyama, T; Terada, H; Tsutsui, H, 1992) |
| "We investigated the effects of early chronic administration of propranolol on systemic and splanchnic hemodynamic changes, and the development of portal-systemic shunts in conscious, unrestrained, portal vein stenosed rats." | 1.28 | Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. ( Cailmail, S; Lebrec, D; Lin, HC; Soubrane, O, 1991) |
| "The results of esophageal varices treatment in two groups of patients are shown." | 1.28 | [Sclerosing treatment of esophageal varices]. ( Jorge, AD; Milutin, C; Oliver, J, 1991) |
| "Propranolol was administered in drinking water to 20 animals for a period of 6 wk at a dose of 10 mg." | 1.28 | Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. ( Bhatnagar, R; Dayal, Y; Groszmann, RJ; Mosca, PG; Reuben, A; Rojkind, M; Sarin, SK; Stadecker, MJ, 1991) |
| "Propranolol has been used to reduce cardiac output and portal pressure in these patients." | 1.28 | Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis. ( Agusti, AG; Bosch, J; Garcia-Pagan, JC; Roca, J; Rodriguez-Roisin, R; Wagner, PD, 1990) |
| "Rats with chronic portal hypertension have an increased gastric mucosal blood flow and an impaired acid secretory response to pentagastrin stimulation." | 1.28 | Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats. ( Bosch, J; Pérez Ayuso, RM; Piqué, JM; Pizcueta, P, 1990) |
| "Since the gastritis is related to vascular changes and congestion of the stomach wall secondary to increased portal pressure, and not inflammation, measures aimed at local healing or surgical removal of the bleeding area fail." | 1.27 | Persistent hemorrhagic gastritis in a patient with portal hypertension and esophagogastric varices: the role of portal decompressive surgery. ( Babb, RR; Mitchell, RL, 1988) |
| "Sclerotherapy of esophageal varices consists in obstruction of the varicosities." | 1.27 | [Prevention of recurrent hemorrhage due to portal hypertension]. ( Lebrec, D, 1986) |
| " Increased dosage of propranolol to 4 mg did not produce any further reduction of portal pressure or mucosal damage." | 1.27 | Propranolol reduces ethanol-induced gastric mucosal damage in portal hypertensive rats. ( Ivey, KJ; Maeda, R; Mason, GR; Sankary, H; Sarfeh, IJ; Tarnawski, A, 1986) |
| "Bleeding from ileal varices can be managed by either local control or portal vein decompression." | 1.27 | Variceal bleeding from an ileostomy stoma. ( Dunn, GD; McGrew, W; Wang, MM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (26.22) | 18.7374 |
| 1990's | 107 (32.62) | 18.2507 |
| 2000's | 65 (19.82) | 29.6817 |
| 2010's | 63 (19.21) | 24.3611 |
| 2020's | 7 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Sychev, DA | 1 |
| Parusov, AI | 1 |
| Loranskaya, ID | 1 |
| Denisenko, NP | 1 |
| Akmalova, KA | 1 |
| Sozaeva, ZA | 1 |
| Turkina, OL | 1 |
| Zastrozhin, MS | 1 |
| Turco, L | 1 |
| Reiberger, T | 3 |
| Vitale, G | 1 |
| La Mura, V | 3 |
| Danielsen, KV | 1 |
| Nabilou, P | 1 |
| Wiese, SS | 1 |
| Hove, JD | 1 |
| Bendtsen, F | 6 |
| Møller, S | 7 |
| Vukotic, R | 2 |
| Di Donato, R | 1 |
| Roncarati, G | 1 |
| Simoni, P | 1 |
| Renzulli, M | 1 |
| Gitto, S | 1 |
| Schepis, F | 2 |
| Villa, E | 1 |
| Berzigotti, A | 5 |
| Bosch, J | 36 |
| Andreone, P | 1 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| Shao, R | 1 |
| Li, Z | 1 |
| Wang, J | 1 |
| Qi, R | 1 |
| Liu, Q | 1 |
| Zhang, W | 1 |
| Mao, X | 1 |
| Song, X | 1 |
| Li, L | 1 |
| Liu, Y | 1 |
| Zhao, X | 1 |
| Liu, C | 1 |
| Li, X | 1 |
| Zuo, C | 1 |
| Wang, W | 1 |
| Qi, X | 1 |
| Afaa, TJ | 1 |
| Amegan-Aho, KH | 1 |
| Richardson, E | 1 |
| Goka, B | 1 |
| Lim, YL | 1 |
| Kim, MY | 6 |
| Jang, YO | 1 |
| Baik, SK | 6 |
| Kwon, SO | 4 |
| McDonald, N | 1 |
| Lilburn, DML | 1 |
| Lachlan, NJ | 1 |
| Macnaught, G | 1 |
| Patel, D | 1 |
| Jayaswal, ANA | 1 |
| Hayes, PC | 6 |
| Semple, SI | 1 |
| Fallowfield, JA | 1 |
| Grammatikopoulos, T | 1 |
| McKiernan, PJ | 1 |
| Dhawan, A | 1 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 2 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Mandorfer, M | 1 |
| Peck-Radosavljevic, M | 2 |
| Rainer, F | 1 |
| Schwabl, P | 1 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Trauner, M | 1 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Bishnu, S | 1 |
| Ahammed, SM | 1 |
| Sarkar, A | 1 |
| Hembram, J | 1 |
| Chatterjee, S | 1 |
| Das, K | 2 |
| Dhali, GK | 1 |
| Chowdhury, A | 1 |
| Baiges, A | 2 |
| Hernández-Gea, V | 3 |
| Lelei-Mailu, FJ | 1 |
| Mariara, CM | 1 |
| Abd Alla, MD | 1 |
| Eid, EMM | 1 |
| Soliman, AIA | 1 |
| Elhawary, MA | 1 |
| Kilany, YF | 1 |
| Abd-Almonaem, G | 1 |
| Bayoumi, SS | 1 |
| Moursy, MRA | 1 |
| Al-Zaem, FAM | 1 |
| de Araújo, LJT | 1 |
| Nagaoka, MR | 1 |
| Borges, DR | 1 |
| Kouyoumdjian, M | 1 |
| Li, LN | 1 |
| Sun, XY | 1 |
| Wang, GC | 1 |
| Tian, XG | 1 |
| Zhang, MY | 1 |
| Jiang, KT | 1 |
| Zhang, CQ | 1 |
| Reverter, E | 2 |
| Lozano, JJ | 1 |
| Alonso, C | 1 |
| Seijo, S | 2 |
| Turon, F | 1 |
| Martínez-Chantar, ML | 1 |
| Mato, JM | 1 |
| Martínez-Arranz, I | 1 |
| García-Pagán, JC | 26 |
| Kim, BH | 1 |
| Chung, JW | 1 |
| Lee, CS | 1 |
| Jang, ES | 1 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Kim, JW | 2 |
| Villanueva, C | 3 |
| Albillos, A | 8 |
| Genescà, J | 3 |
| Calleja, JL | 3 |
| Aracil, C | 3 |
| Bañares, R | 7 |
| Morillas, RM | 2 |
| Poca, M | 2 |
| Peñas, B | 2 |
| Augustin, S | 3 |
| Abraldes, JG | 11 |
| Alvarado, E | 1 |
| Torres, F | 1 |
| Zaghloul, SG | 1 |
| Wahab, EA | 1 |
| Seleem, WM | 1 |
| Hanafy, AS | 1 |
| Gomaa, AF | 1 |
| Lakouz, K | 1 |
| Amin, AI | 1 |
| Carrión, JA | 1 |
| Forns, X | 1 |
| García-Valdecasas, JC | 1 |
| Navasa, M | 4 |
| Kong, DR | 3 |
| Zhang, C | 1 |
| Zhang, L | 2 |
| Wang, JG | 3 |
| Xiong, Z | 1 |
| Li, P | 2 |
| Xu, JM | 3 |
| Upreti, V | 1 |
| Dhull, P | 1 |
| Patnaik, SK | 1 |
| Kumar, KV | 1 |
| Gupta, N | 2 |
| Kumar, A | 4 |
| Sharma, P | 3 |
| Garg, V | 1 |
| Sharma, BC | 4 |
| Sarin, SK | 7 |
| Heebøll, S | 1 |
| Villadsen, GE | 1 |
| Aagaard, NK | 1 |
| Grønbæk, H | 2 |
| Vilstrup, H | 1 |
| Keiding, S | 1 |
| Ma, C | 1 |
| Wang, M | 1 |
| Chen, C | 2 |
| Hao, JH | 1 |
| Hobolth, L | 3 |
| Hansen, EF | 1 |
| Sinagra, E | 1 |
| Perricone, G | 1 |
| D'Amico, M | 2 |
| Tinè, F | 2 |
| D'Amico, G | 3 |
| Kimer, N | 1 |
| Feineis, M | 1 |
| Lee, PC | 1 |
| Yang, YY | 2 |
| Lee, WP | 1 |
| Lee, KC | 1 |
| Hsieh, YC | 1 |
| Lee, TY | 1 |
| Lin, HC | 8 |
| Celtik, C | 1 |
| Durmaz, O | 1 |
| Oner, N | 1 |
| Yavuz, T | 1 |
| Gökce, S | 1 |
| Aydogan, A | 1 |
| Nisli, K | 1 |
| Emiroglu, HH | 1 |
| Ömeroglu, RE | 1 |
| Sökücü, S | 2 |
| El-Karaksy, HM | 1 |
| El-Koofy, N | 1 |
| Mohsen, N | 1 |
| Helmy, H | 1 |
| Nabil, N | 1 |
| El-Shabrawi, M | 2 |
| Kim, JH | 1 |
| Kim, JM | 1 |
| Cho, YZ | 1 |
| Na, JH | 1 |
| Kim, HS | 3 |
| Kim, HA | 1 |
| Kang, HW | 1 |
| Cha, SH | 1 |
| Kim, YJ | 3 |
| Poddar, U | 1 |
| Shava, U | 1 |
| Yachha, SK | 1 |
| Agarwal, J | 1 |
| Kumar, S | 1 |
| Baijal, SS | 1 |
| Srivastava, A | 1 |
| Iwakiri, Y | 1 |
| Sun, B | 1 |
| Wang, MQ | 1 |
| Yu, FF | 1 |
| Tripathi, DM | 1 |
| Erice, E | 2 |
| Lafoz, E | 1 |
| García-Calderó, H | 1 |
| Gracia-Sancho, J | 1 |
| Morillas, R | 1 |
| Pavel, O | 1 |
| Wang, D | 1 |
| Wang, Q | 2 |
| Yin, J | 1 |
| Dong, R | 1 |
| Du, X | 1 |
| Lu, J | 1 |
| Kalambokis, GN | 1 |
| Baltayiannis, G | 1 |
| Christou, L | 1 |
| Christodoulou, D | 1 |
| Brito-Azevedo, A | 2 |
| Perez, Rde M | 1 |
| Coelho, HS | 2 |
| Fernandes, Ede S | 1 |
| Castiglione, RC | 2 |
| Villela-Nogueira, CA | 2 |
| Bouskela, E | 2 |
| Li, T | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Perez, RM | 1 |
| Fernandes, ES | 1 |
| Kim, SG | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Alatsakis, M | 2 |
| Ballas, KD | 1 |
| Pavlidis, TE | 1 |
| Psarras, K | 2 |
| Rafailidis, S | 2 |
| Tzioufa-Asimakopoulou, V | 2 |
| Marakis, GN | 1 |
| Sakantamis, AK | 1 |
| Lebrec, L | 1 |
| Colomo, A | 1 |
| López-Balaguer, JM | 1 |
| Alvarez-Urturi, C | 1 |
| Torras, X | 1 |
| Balanzó, J | 1 |
| Guarner, C | 1 |
| Zhang, ZQ | 1 |
| Shi, B | 1 |
| Wu, GQ | 1 |
| Qin, KR | 1 |
| Jiang, ZL | 1 |
| Zhu, L | 1 |
| Jha, SK | 2 |
| Dubey, S | 1 |
| Tyagi, P | 1 |
| Raffa, S | 1 |
| Retto, O | 1 |
| Farias, AQ | 1 |
| Kassab, F | 1 |
| da Rocha, EC | 1 |
| Dos Santos Bomfim, V | 1 |
| Vezozzo, DC | 1 |
| Bittencourt, PL | 1 |
| Carrilho, FJ | 1 |
| Demertzidis, C | 1 |
| Ballas, K | 1 |
| Symeonidis, N | 1 |
| Pavlidis, T | 1 |
| Sakadamis, A | 1 |
| Trebicka, J | 1 |
| Hennenberg, M | 1 |
| Schulze Pröbsting, A | 1 |
| Laleman, W | 2 |
| Klein, S | 1 |
| Granzow, M | 1 |
| Nevens, F | 4 |
| Zaagsma, J | 1 |
| Heller, J | 3 |
| Sauerbruch, T | 8 |
| Tripathi, D | 1 |
| Jha, S | 1 |
| Mishra, SR | 2 |
| Kaltoft, N | 1 |
| Agrawal, A | 1 |
| Thevenot, T | 2 |
| Cervoni, JP | 2 |
| Monnet, E | 1 |
| Sheppard, F | 1 |
| Martino, VD | 1 |
| Pastore, S | 1 |
| Londero, M | 1 |
| Cont, G | 1 |
| Di Leo, G | 1 |
| Ventura, A | 1 |
| Juraschek, SP | 1 |
| Bankova, L | 1 |
| Falade, O | 1 |
| Chow, G | 1 |
| McKenzie, R | 1 |
| Bhogal, HK | 1 |
| Di Martino, V | 1 |
| Zaky, S | 1 |
| Fouad, EA | 1 |
| Kotb, HI | 1 |
| Angeli, P | 1 |
| Bocci, V | 1 |
| Zanardi, I | 1 |
| Travagli, V | 1 |
| Lee, JY | 1 |
| Huo, TI | 1 |
| Huang, HC | 2 |
| Lee, FY | 3 |
| Chuang, CL | 1 |
| Chang, CC | 2 |
| Wang, SS | 2 |
| Lee, SD | 5 |
| Catalina, MV | 1 |
| Ripoll, C | 1 |
| Rincón, D | 1 |
| Hassanin, F | 1 |
| Payer, BA | 1 |
| Pinter, M | 1 |
| Homoncik, M | 1 |
| Roelsgaard, K | 1 |
| Feldager Hansen, E | 1 |
| Mejías, M | 1 |
| García-Pras, E | 1 |
| Fernández, M | 3 |
| Llop, E | 1 |
| Conget, I | 1 |
| Grimaldi, C | 1 |
| de Ville de Goyet, J | 1 |
| Nobili, V | 1 |
| Coll, M | 1 |
| Rodriguez, S | 1 |
| Raurell, I | 1 |
| Ezkurdia, N | 1 |
| Brull, A | 1 |
| Guardia, J | 1 |
| Esteban, R | 1 |
| Martell, M | 1 |
| dos Santos, JM | 1 |
| Ferreira, AR | 1 |
| Fagundes, ED | 1 |
| Ferreira, AP | 1 |
| Ferreira, LS | 1 |
| Magalhães, MC | 1 |
| Bittencourt, PF | 1 |
| Carvalho, SD | 1 |
| Figueiredo Filho, PP | 1 |
| Penna, FJ | 1 |
| Agasti, AK | 1 |
| Mahajan, AU | 1 |
| Phadke, AY | 1 |
| Nathani, PJ | 1 |
| Sawant, P | 1 |
| Reboredo, M | 1 |
| Chang, HC | 1 |
| Barbero, R | 1 |
| Rodríguez-Ortigosa, CM | 1 |
| Pérez-Vizcaíno, F | 1 |
| Morán, A | 1 |
| García, M | 1 |
| Banales, JM | 1 |
| Carreño, N | 1 |
| Alegre, F | 1 |
| Herrero, I | 1 |
| Quiroga, J | 1 |
| Prieto, J | 1 |
| Sangro, B | 1 |
| Wu, CY | 1 |
| Yeh, HZ | 1 |
| Chen, GH | 1 |
| Brensing, KA | 1 |
| Hörsch, M | 1 |
| Textor, J | 1 |
| Schiedermaier, P | 2 |
| Raab, P | 2 |
| Schepke, M | 4 |
| Strunk, H | 1 |
| Schild, H | 1 |
| Bureau, C | 1 |
| Péron, JM | 1 |
| Alric, L | 1 |
| Morales, J | 1 |
| Sanchez, J | 1 |
| Barange, K | 2 |
| Payen, JL | 3 |
| Vinel, JP | 5 |
| Moitinho, E | 6 |
| Matilla, A | 1 |
| Lampreave, JL | 1 |
| Piera, C | 2 |
| De Diego, A | 2 |
| Bellis, L | 1 |
| Graupera, M | 1 |
| Rodés, J | 13 |
| Liang, YG | 1 |
| Chu, XJ | 1 |
| Venon, WD | 1 |
| Baronio, M | 1 |
| Leone, N | 1 |
| Rolfo, E | 1 |
| Fadda, M | 1 |
| Barletti, C | 1 |
| Todros, L | 1 |
| Saracco, G | 1 |
| Rizzetto, M | 1 |
| Tarantino, I | 1 |
| Turnes, J | 2 |
| Orban-Schiopu, AM | 1 |
| Popescu, CR | 1 |
| Blendis, L | 2 |
| Lurie, Y | 1 |
| Oren, R | 1 |
| Blendis, LM | 2 |
| Wong, F | 2 |
| De, BK | 3 |
| Bandyopadhyay, K | 1 |
| Das, TK | 1 |
| Das, D | 2 |
| Biswas, PK | 3 |
| Majumdar, D | 2 |
| Mandal, SK | 2 |
| Ray, S | 1 |
| Dasgupta, S | 1 |
| Süoglu, OD | 1 |
| Elkabes, B | 1 |
| Saner, G | 1 |
| Khan, AA | 1 |
| Sarwar, S | 1 |
| Alam, A | 1 |
| Butt, AK | 1 |
| Shafqat, F | 1 |
| Tarique, S | 1 |
| Ahmed, I | 1 |
| Alvi, A | 1 |
| Niazi, A | 1 |
| Koch, L | 1 |
| Stoffel-Wagner, B | 2 |
| Layer, G | 1 |
| Park, DH | 2 |
| Choi, YJ | 1 |
| Lee, DK | 1 |
| Park, JW | 1 |
| Chang, SJ | 2 |
| Hemstreet, BA | 1 |
| El-Husseini, R | 1 |
| Kaplan, MM | 1 |
| Henriksen, JH | 2 |
| Fuglsang, S | 1 |
| Christensen, E | 1 |
| Hou, MC | 3 |
| Huang, YT | 4 |
| Tadzhiev, IIa | 1 |
| Sergienko, VB | 1 |
| Tsodikov, GV | 1 |
| Tadzhieva, NI | 1 |
| Topchiashvili, ZA | 1 |
| Sapozhkova, LP | 1 |
| Geĭnits, AV | 1 |
| Cales, P | 11 |
| Jutabha, R | 1 |
| Jensen, DM | 1 |
| Martin, P | 1 |
| Savides, T | 1 |
| Han, SH | 1 |
| Gornbein, J | 1 |
| Orban Schiopu, AM | 1 |
| Balas, BI | 1 |
| Diculescu, M | 1 |
| Psilopoulos, D | 1 |
| Galanis, P | 1 |
| Goulas, S | 1 |
| Papanikolaou, IS | 1 |
| Elefsiniotis, I | 1 |
| Liatsos, C | 1 |
| Sparos, L | 1 |
| Mavrogiannis, C | 1 |
| Chan, CC | 1 |
| Chang, FY | 1 |
| Tai, CC | 1 |
| Hernández-Guerra, M | 1 |
| Bellot, P | 1 |
| Oliva, R | 1 |
| Andreu, V | 2 |
| Lionetti, R | 1 |
| Hernández, FT | 1 |
| Zapater, P | 1 |
| De-Madaria, E | 1 |
| Palazón, JM | 1 |
| Pascual, S | 1 |
| Irurzun, J | 1 |
| Such, J | 1 |
| Perez-Mateo, M | 1 |
| Horga, JF | 1 |
| Garrido, A | 2 |
| Márquez, JL | 1 |
| Iglesias, A | 1 |
| Peiró, J | 1 |
| Grilo, I | 1 |
| Garzón, M | 1 |
| Noubibou, M | 1 |
| Douala, HC | 1 |
| Druez, PM | 1 |
| Kartheuser, AH | 1 |
| Kartheuzer, AH | 1 |
| Detry, RJ | 1 |
| Geubel, AP | 1 |
| Huo, LJ | 1 |
| Huang, HF | 1 |
| Yang, BY | 1 |
| Aller, MA | 1 |
| Arias, J | 1 |
| van der Wouden, EJ | 1 |
| Westerveld, BD | 1 |
| Senzolo, M | 1 |
| Cholongitas, E | 1 |
| Marelli, L | 1 |
| Thalheimer, U | 1 |
| Patch, D | 2 |
| Burroughs, AK | 3 |
| Lin, JS | 1 |
| Chan, CY | 1 |
| Yang, C | 1 |
| Wang, YH | 1 |
| Chiou, HY | 1 |
| Su, YC | 1 |
| Lim, DW | 1 |
| Lee, SS | 5 |
| Charpignon, C | 1 |
| Oberti, F | 4 |
| Bernard, P | 1 |
| Bartoli, ER | 1 |
| Pauwels, A | 1 |
| Renard, P | 1 |
| Cadranel, JF | 1 |
| Bernard-Chabert, B | 1 |
| Barbare, JC | 1 |
| Ingrand, I | 1 |
| Ingrand, P | 1 |
| Beauchant, M | 1 |
| Kovacević, N | 1 |
| Tomić, D | 1 |
| Perisić-Savić, M | 1 |
| Grbić, R | 1 |
| Wiest, R | 1 |
| Flacke, S | 1 |
| Herold, T | 1 |
| Ghauri, M | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Lebrec, D | 24 |
| Nouel, O | 1 |
| Corbic, M | 1 |
| Benhamou, JP | 2 |
| Wilkinson, RP | 1 |
| Dominguez, P | 1 |
| Reding, P | 1 |
| van Buuren, HR | 1 |
| van der Velden, PC | 1 |
| Koorevaar, G | 1 |
| Silberbusch, J | 1 |
| Colman, JC | 1 |
| Jennings, GL | 1 |
| McLean, AJ | 1 |
| Mignot, PR | 1 |
| Dudley, FJ | 1 |
| Shepherd, AN | 1 |
| Bouchier, IA | 3 |
| Rueff, B | 1 |
| Hayes, P | 1 |
| Mills, PR | 1 |
| Rae, AP | 1 |
| Farah, DA | 1 |
| Russell, RI | 1 |
| Lorimer, AR | 1 |
| Carter, DC | 2 |
| Korman, MG | 1 |
| Bizer, LS | 1 |
| Dobrilla, G | 1 |
| de Pretis, G | 2 |
| Braillon, A | 8 |
| Resnick, RH | 1 |
| Anderberg, B | 1 |
| Andersson, PA | 1 |
| Heuman, R | 1 |
| Jansson, L | 1 |
| Jorfeldt, L | 1 |
| Rutberg, H | 1 |
| Sjödahl, R | 1 |
| Cario, WR | 1 |
| Westaby, D | 1 |
| Bihari, DJ | 1 |
| Gimson, AE | 1 |
| Crossley, IR | 1 |
| Williams, R | 1 |
| Gupta, KM | 1 |
| Chadda, S | 1 |
| Chadda, VS | 2 |
| Panwar, RB | 1 |
| Sharda, DP | 1 |
| Mishra, SN | 1 |
| Chaudhary, A | 1 |
| Gitlin, N | 1 |
| Bleichner, G | 1 |
| Parent, A | 1 |
| Raffray, Y | 1 |
| Squara, P | 1 |
| Chevrel, B | 1 |
| Hillon, P | 1 |
| Blanchet, L | 1 |
| Cuccurullo, F | 1 |
| Seccia, G | 1 |
| Porreca, E | 1 |
| Guglielmi, MD | 1 |
| Mezzetti, A | 1 |
| Tomassetti, V | 1 |
| Marzio, L | 1 |
| Lledó, JL | 1 |
| Rossi, I | 1 |
| Pérez-Páramo, M | 2 |
| Tabuenca, MJ | 1 |
| Iborra, J | 3 |
| Escartín, P | 2 |
| Wu, ZY | 1 |
| Benoit, JN | 1 |
| Maruyama, T | 1 |
| Nakamura, M | 1 |
| Ohishi, A | 1 |
| Watanabe, R | 1 |
| Kaneko, K | 1 |
| Aosaki, N | 1 |
| Iigaya, T | 1 |
| Monma, T | 1 |
| Sugiura, H | 1 |
| Miyoshi, Y | 1 |
| Hamaguchi, K | 1 |
| Luca, A | 3 |
| Feu, F | 8 |
| Lopez-Talavera, JC | 1 |
| Bru, C | 2 |
| Komeichi, H | 2 |
| Moreau, R | 6 |
| Cailmail, S | 5 |
| Gaudin, C | 1 |
| Caillau, H | 1 |
| Crambes, O | 1 |
| Desmorat, H | 2 |
| Rocher, I | 1 |
| Jung, L | 1 |
| Urien, S | 1 |
| Brouard, R | 1 |
| Pascal, JP | 5 |
| Yat, PC | 1 |
| Cho, CH | 1 |
| Shigemori, H | 1 |
| Iwao, T | 4 |
| Ikegami, M | 1 |
| Toyonaga, A | 4 |
| Tanikawa, K | 2 |
| Vickers, C | 1 |
| Rhodes, J | 1 |
| Chesner, I | 1 |
| Hillenbrand, P | 1 |
| Dawson, J | 1 |
| Cockel, R | 1 |
| Adams, D | 1 |
| O'Connor, H | 1 |
| Dykes, P | 1 |
| Bradby, H | 1 |
| Bołdys, H | 1 |
| Hartleb, M | 1 |
| Rudzki, K | 1 |
| Nowak, A | 1 |
| Nowak, S | 1 |
| el Tourabi, H | 1 |
| el Amin, AA | 1 |
| Shaheen, M | 1 |
| Woda, SA | 1 |
| Homeida, M | 1 |
| Harron, DW | 1 |
| Planas, R | 1 |
| Cabré, E | 1 |
| Galán, A | 1 |
| Quer, JC | 1 |
| García Pagán, JC | 1 |
| Gassull, MA | 1 |
| Ladero Quesada, JM | 1 |
| Díez Ordóñez, S | 1 |
| Gallego Beuter, JJ | 1 |
| Hernández Lezana, A | 1 |
| Herraiz Serrano, ML | 1 |
| Díaz-Rubio García, M | 1 |
| Ohsuga, M | 2 |
| Pizcueta, P | 3 |
| Tincani, E | 2 |
| Cioni, G | 2 |
| Cristani, A | 2 |
| D'Alimonte, P | 2 |
| Vignoli, A | 1 |
| Abbati, G | 1 |
| Ventura, P | 1 |
| Romagnoli, R | 2 |
| Ventura, E | 2 |
| Gilmore, GT | 1 |
| Henderson, JM | 1 |
| Mackay, G | 1 |
| Galloway, JR | 1 |
| Bordas, JM | 3 |
| Escorsell, A | 5 |
| Acharya, SK | 1 |
| Dasarathy, S | 1 |
| Saksena, S | 1 |
| Pande, JN | 1 |
| Polio, J | 1 |
| Sieber, CC | 2 |
| Lerner, E | 1 |
| Groszmann, RJ | 5 |
| Vorobioff, J | 1 |
| Picabea, E | 1 |
| Gamen, M | 1 |
| Villavicencio, R | 1 |
| Bordato, J | 1 |
| Bessone, F | 1 |
| Tanno, H | 1 |
| Palazzi, J | 1 |
| Sarano, H | 1 |
| Pozzoli, L | 1 |
| Panés, J | 2 |
| Piqué, JM | 4 |
| Terés, J | 1 |
| Melissant, CF | 1 |
| Smith, SJ | 1 |
| Kazzaz, BA | 1 |
| Demedts, M | 1 |
| Sogni, P | 2 |
| Hadengue, A | 4 |
| Barrett, AE | 1 |
| Navaratnam, RM | 1 |
| Lemberger, RJ | 1 |
| Turrini, F | 1 |
| Lijnen, P | 1 |
| VanBilloen, H | 1 |
| Fevery, J | 1 |
| Elsayed, SS | 1 |
| Shiha, G | 1 |
| Hamid, M | 1 |
| Farag, FM | 1 |
| Azzam, F | 1 |
| Awad, M | 1 |
| Combis, JM | 1 |
| Badia, P | 1 |
| Combis, F | 1 |
| Bandi, JC | 2 |
| Casado, M | 2 |
| Pienkowski, P | 1 |
| Sozzani, P | 1 |
| Kervran, A | 1 |
| Frexinos, J | 1 |
| Hori, N | 1 |
| Okanoue, T | 1 |
| Sawa, Y | 1 |
| Mori, T | 1 |
| Kashima, K | 1 |
| Hermann, R | 1 |
| Mies, S | 1 |
| Neto, OB | 1 |
| Beer, A | 1 |
| Baía, CE | 1 |
| Alfieri, F | 1 |
| Pereira, LM | 1 |
| Sette, MJ | 1 |
| Raia, S | 1 |
| Rifflet, H | 1 |
| Maïga, MY | 1 |
| Pilette, C | 1 |
| Gallois, Y | 1 |
| Douay, O | 1 |
| Le Jeune, JJ | 1 |
| Saumet, JL | 1 |
| Tsai, JF | 1 |
| Hong, CY | 3 |
| Gadano, A | 1 |
| Valla, D | 2 |
| Zoller, WG | 2 |
| Gross, M | 1 |
| Liu, TB | 1 |
| Yang, MC | 1 |
| Alvarez, F | 1 |
| Cheng, YR | 1 |
| Saigal, S | 1 |
| Chawla, Y | 1 |
| Dilawari, JB | 1 |
| Oho, K | 2 |
| Sakai, T | 1 |
| Sato, M | 1 |
| Nakano, R | 1 |
| Yamayaki, M | 1 |
| Cacho, G | 1 |
| McCormick, PA | 2 |
| Greenslade, L | 1 |
| Chin, J | 1 |
| McIntyre, N | 1 |
| Scheurlen, C | 1 |
| Roleff, A | 1 |
| Neubrand, M | 1 |
| Sumanovski, LT | 1 |
| Battegay, E | 1 |
| Stumm, M | 1 |
| van der Kooij, M | 1 |
| Lamba, GS | 1 |
| Kumar, M | 1 |
| Misra, A | 1 |
| Murthy, NS | 1 |
| Ghoshal, UC | 1 |
| Das, T | 1 |
| Santra, A | 1 |
| Castaño, G | 2 |
| Viudez, P | 2 |
| Carlevaro, O | 1 |
| Ocampo, C | 1 |
| Zandalazini, H | 1 |
| Riccitelli, M | 1 |
| Sookoian, S | 2 |
| Frider, B | 2 |
| Piqueras, B | 1 |
| Schreiber, RA | 1 |
| Shashidhar, H | 1 |
| Langhans, N | 1 |
| Grand, RJ | 1 |
| Hoppe, A | 1 |
| Brensing, K | 1 |
| Paar, D | 1 |
| Potyka, U | 1 |
| Pateron, D | 1 |
| Tazi, KA | 1 |
| Chagneau, C | 1 |
| Poirel, O | 1 |
| Philippe, M | 1 |
| Orozco, H | 1 |
| Mercado, MA | 1 |
| Chan, C | 1 |
| Guillén-Navarro, E | 1 |
| López-Martínez, LM | 1 |
| Bhalla, A | 1 |
| Tripkovic, M | 1 |
| Kozjek, F | 1 |
| Krizman, I | 1 |
| Jereb, J | 1 |
| Francetic, I | 1 |
| Grabnar, I | 1 |
| Mrhar, A | 1 |
| Lowe, RC | 1 |
| Grace, ND | 2 |
| Lo, GH | 1 |
| Lai, KH | 2 |
| Cheng, JS | 1 |
| Hsu, PI | 1 |
| Chen, TA | 1 |
| Wang, EM | 1 |
| Lin, CK | 1 |
| Chiang, HT | 1 |
| Shah, SR | 1 |
| Hilzenrat, N | 1 |
| Arish, A | 1 |
| Yaari, A | 1 |
| Sikuler, E | 1 |
| González-Abraldes, J | 1 |
| Del Arbol, LR | 1 |
| Rodríguez, C | 1 |
| González, M | 1 |
| Perello, A | 1 |
| Sakai, K | 1 |
| Sata, M | 1 |
| Sen, S | 1 |
| Maity, AK | 1 |
| Gustavo, C | 1 |
| Pedro, V | 1 |
| Bernardo, F | 1 |
| Silvia, S | 1 |
| Ulrich, B | 1 |
| Poilleux, J | 1 |
| Damamme, B | 1 |
| Da Silva, LC | 1 |
| Muñoz, SJ | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Aramaki, T | 1 |
| Sekiyama, T | 1 |
| Katsuta, Y | 1 |
| Kurokawa, H | 1 |
| Tsutsui, H | 1 |
| Terada, H | 1 |
| Satomura, K | 1 |
| Okumura, H | 1 |
| Garden, OJ | 1 |
| Triger, DR | 1 |
| Sabbà, C | 1 |
| Ferraioli, G | 1 |
| Buonamico, P | 1 |
| Berardi, E | 1 |
| Antonica, G | 1 |
| Taylor, KJ | 1 |
| Albano, O | 1 |
| Monnin, JL | 1 |
| Le Quellec, A | 1 |
| Taourel, P | 1 |
| Bruel, JM | 1 |
| Blanc, F | 1 |
| Michel, H | 1 |
| Ciurana, AJ | 1 |
| Ozsoylu, S | 2 |
| Koçak, N | 2 |
| Yüce, A | 2 |
| Ozbag, E | 1 |
| Pomier-Layrargues, G | 1 |
| Giroux, L | 1 |
| Rocheleau, B | 1 |
| Huet, PM | 1 |
| Otaguro, JE | 1 |
| Hart, LL | 1 |
| Wruck, U | 1 |
| Wermke, W | 1 |
| Brady, CE | 1 |
| Testa, R | 1 |
| Rodriguez, G | 1 |
| Dagnino, F | 1 |
| Grasso, A | 1 |
| Gris, A | 1 |
| Marenco, S | 1 |
| Nobili, F | 1 |
| Risso, D | 1 |
| Rosadini, G | 1 |
| Celle, G | 1 |
| Pérez-Ayuso, RM | 2 |
| González, A | 1 |
| Pérez, R | 1 |
| Rigau, J | 1 |
| Quintero, E | 1 |
| Valderrama, R | 1 |
| Viver, J | 1 |
| Soubrane, O | 1 |
| Hüppe, D | 1 |
| May, B | 1 |
| Martin, T | 1 |
| Taupignon, A | 1 |
| Lavignolle, A | 1 |
| Perrin, D | 1 |
| Le Bodic, L | 1 |
| Altmann, O | 1 |
| Jorge, AD | 1 |
| Milutin, C | 1 |
| Oliver, J | 1 |
| Geller, LI | 1 |
| Vorob'ev, LP | 1 |
| Maev, IV | 1 |
| Andreev, NG | 1 |
| Mosca, PG | 1 |
| Rojkind, M | 1 |
| Stadecker, MJ | 1 |
| Bhatnagar, R | 1 |
| Reuben, A | 1 |
| Dayal, Y | 1 |
| Davis, JM | 1 |
| Lewis, JA | 1 |
| Conn, HO | 2 |
| Wright, SC | 1 |
| Matloff, DS | 1 |
| Garcia-Tsao, G | 1 |
| Fisher, RL | 1 |
| Rikkers, LF | 1 |
| Choudhary, A | 1 |
| Dogra, J | 1 |
| Sulemani, AA | 1 |
| Misra, SN | 1 |
| Eugène, C | 1 |
| Vitte, RL | 1 |
| Anciaux, ML | 1 |
| Qureshi, H | 1 |
| Zuberi, SJ | 1 |
| Alam, E | 1 |
| Agusti, AG | 1 |
| Roca, J | 1 |
| Wagner, PD | 1 |
| Rodriguez-Roisin, R | 1 |
| Pérez Ayuso, RM | 1 |
| Kiire, CF | 1 |
| Terada, M | 1 |
| Notsumata, K | 2 |
| Unoura, M | 1 |
| Kobayashi, K | 1 |
| Hattori, N | 1 |
| Grasset, D | 1 |
| Ravaud, A | 1 |
| Meskens, C | 1 |
| Blanc, M | 1 |
| Cotonat, J | 1 |
| Roulot, D | 1 |
| Sayegh, R | 1 |
| Bondarenko, IP | 1 |
| Dubinskiĭ, AA | 1 |
| Tereshkin, IG | 1 |
| Pagliaro, L | 2 |
| Pasta, L | 2 |
| Sotto, A | 1 |
| Castro, R | 1 |
| Glez Cansino, J | 1 |
| Yen, CK | 1 |
| Koblik, P | 1 |
| Breznock, B | 1 |
| Komtebedde, J | 1 |
| Pollycove, M | 1 |
| Hornof, WJ | 1 |
| Fisher, P | 1 |
| Kroeger, RJ | 1 |
| Miotti, T | 1 |
| Reichen, J | 2 |
| McLaren, MI | 1 |
| Taylor, I | 1 |
| Rector, WG | 2 |
| Ohara, N | 1 |
| Geoffroy, P | 3 |
| Sauvanet, JP | 1 |
| Cerini, R | 2 |
| Koshy, A | 2 |
| Girod, C | 4 |
| Jensen, LS | 1 |
| Krarup, N | 1 |
| Juhl, CO | 1 |
| Nielsen, TH | 1 |
| Larsen, JA | 1 |
| Dunk, AA | 1 |
| Moore, J | 1 |
| Symon, A | 1 |
| Dickie, A | 1 |
| Sinclair, TS | 1 |
| Mowat, NA | 1 |
| Brunt, PW | 1 |
| Mastai, R | 1 |
| Kravetz, D | 1 |
| Bruix, J | 1 |
| Viola, C | 1 |
| Alexandrino, PT | 1 |
| Alves, MM | 1 |
| Pinto Correia, J | 1 |
| Wu, XN | 2 |
| Gu, JK | 1 |
| Wang, GL | 1 |
| Ding, MM | 1 |
| Sukigara, M | 1 |
| Shimoji, K | 1 |
| Ohata, M | 1 |
| Matsumoto, T | 1 |
| Komazaki, T | 1 |
| Matsumura, M | 1 |
| Itoh, S | 1 |
| Omoto, R | 1 |
| Salmon, RJ | 1 |
| Uzzan, J | 1 |
| Girodet, J | 1 |
| Gislon, J | 1 |
| Babb, RR | 1 |
| Mitchell, RL | 1 |
| Snady, H | 1 |
| Lieber, CS | 1 |
| Jirón, MI | 2 |
| Mella, JG | 1 |
| Mánquez, P | 1 |
| Kauer, G | 1 |
| Wolff, C | 1 |
| Jabsa, Z | 1 |
| Soto, JR | 1 |
| Armas-Merino, R | 1 |
| Deflandre, J | 1 |
| Gillard, V | 1 |
| Pirotte, J | 1 |
| el Allaf, D | 1 |
| Carlier, J | 1 |
| Filippazzo, MG | 1 |
| Morabito, A | 1 |
| Ferrari, A | 1 |
| Marenco, G | 1 |
| Mazzone, O | 1 |
| Randazzo, G | 1 |
| Catalano, D | 1 |
| Noè, I | 1 |
| Cello, JP | 1 |
| Crass, RA | 1 |
| Grendell, JH | 1 |
| Trunkey, DD | 1 |
| Queuniet, AM | 1 |
| Czernichow, P | 1 |
| Lerebours, E | 1 |
| Ducrotte, P | 1 |
| Tranvouez, JL | 1 |
| Colin, R | 1 |
| Duchateau, A | 1 |
| Thiéfin, G | 1 |
| Zeitoun, P | 1 |
| Baldassarre, G | 1 |
| Ventrella, F | 1 |
| Gadaleta, CD | 1 |
| Heloury, Y | 1 |
| Valayer, J | 1 |
| Hay, JM | 1 |
| Gauthier, F | 1 |
| Alagille, D | 1 |
| Kong, CW | 1 |
| Lay, CS | 1 |
| Tsai, YT | 1 |
| Lo, KJ | 1 |
| Chiang, BN | 1 |
| Scheurlen, M | 1 |
| Egberts, EH | 1 |
| Dölle, W | 1 |
| Ohnishi, K | 1 |
| Nakayama, T | 1 |
| Saito, M | 1 |
| Hatano, H | 1 |
| Tsukamoto, T | 1 |
| Terabayashi, H | 1 |
| Sugita, S | 1 |
| Wada, K | 1 |
| Nomura, F | 1 |
| Koen, H | 1 |
| Sankary, H | 1 |
| Sarfeh, IJ | 1 |
| Tarnawski, A | 1 |
| Maeda, R | 1 |
| Ivey, KJ | 1 |
| Mason, GR | 1 |
| Arthur, MJ | 1 |
| Tanner, AR | 1 |
| Patel, C | 1 |
| Wright, R | 1 |
| Renwick, AG | 1 |
| George, CF | 1 |
| Wang, MM | 1 |
| McGrew, W | 1 |
| Dunn, GD | 1 |
| Nakajima, K | 1 |
| Hirosawa, K | 1 |
| Onoda, B | 1 |
| Teichmann, W | 1 |
| Schäbitz, J | 1 |
| Lukesch, KH | 1 |
| Schmidt, GA | 1 |
| Rikirsch, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803)[NCT03783065] | 40 participants (Anticipated) | Interventional | 2019-01-02 | Recruiting | |||
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial[NCT01282398] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-04-30 | Not yet recruiting | ||
| Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices[NCT02740166] | Phase 4 | 212 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial[NCT01000779] | Phase 3 | 100 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576] | 12 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Poor enrollment of study population) | |||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices[NCT00493480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| Is Capsule Endoscopy Accurate and Cost-effective Enough to Screen Cirrhotic Patients for Varices & Other Lesions?[NCT01079416] | 65 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| Propanolol for Primary Prophylaxis for Variceal Bleed in Biliary Atresia - An Open Label Randomized Controlled Study[NCT04494763] | 92 participants (Anticipated) | Interventional | 2020-08-15 | Recruiting | |||
| Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis[NCT00006398] | Phase 3 | 213 participants (Actual) | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02123576)
Timeframe: baseline and 14 days
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | 0.48 |
| Placebo | 0.03 |
Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 3 |
| Placebo | 3 |
We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 2 |
We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year
| Intervention | days (Mean) |
|---|---|
| Treatment | 102 |
| Placebo | 59 |
(NCT02123576)
Timeframe: day 30 and 180
| Intervention | days (Mean) |
|---|---|
| Treatment | 80 |
| Placebo | 36 |
48 reviews available for propranolol and Hypertension, Portal
| Article | Year |
|---|---|
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
Portal hypertension and its management in children.
Topics: Adrenergic beta-Antagonists; Child; Consensus; Endoscopy; Gastrointestinal Hemorrhage; Guidelines as | 2018 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Hemodynamics; Hepatic Veins; Humans; Hypertensi | 2014 |
Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Case-Control Studies; Esophageal and Gastric Varices; Fe | 2015 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta-blockers in the prevention of gastrointestinal bleeding.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Esophageal and Gastr | 1990 |
The role of carvedilol in the management of portal hypertension.
Topics: Antihypertensive Agents; Ascites; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combination; Et | 2010 |
Prognostic markers in patients who have recovered from an acute variceal bleeding: role of HVPG measurement.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Biomarkers; Esophageal and Gastric Varices; Ga | 2011 |
Propranolol safety profile in children.
Topics: Adrenergic beta-Antagonists; Age Factors; Angina Pectoris; Central Nervous System Diseases; Child; D | 2011 |
Evaluation of carvedilol for the treatment of portal hypertension.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fibrosis; Humans; Hy | 2004 |
Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Animals; Contraindications; Drug Therapy, Combination; Endoscopy; Esoph | 2006 |
[The effect of propranolol on portal hypertension].
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 1992 |
[New therapeutic possibilities of propranolol].
Topics: Antithyroid Agents; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; | 1984 |
Medical treatment of portal hypertension and oesophageal varices.
Topics: Blood Flow Velocity; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hem | 1983 |
Management of upper gastrointestinal haemorrhage.
Topics: Adult; Aged; Combined Modality Therapy; Embolization, Therapeutic; Esophageal and Gastric Varices; E | 1983 |
Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis.
Topics: Animals; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; | 1984 |
[Portal hypertension: value of combination of nitrate derivatives and beta blockers for better prevention?].
Topics: Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Portal; Isosorbide Dinitrate; | 1995 |
New approaches in the pharmacologic treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Humans; Hypertension, Portal; Propranolol; Serotonin Antagonists; Spiro | 1993 |
[Vasodilators and renal function in cirrhosis].
Topics: Drug Therapy, Combination; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Propranolol; Vasod | 1995 |
[Gastropathy due to portal hypertension].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diagnosis, Differential; Gastritis | 1997 |
Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointest | 1996 |
Portal-hypertensive gastropathy.
Topics: Esophageal and Gastric Varices; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; H | 1998 |
The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination | 2000 |
Pharmacologic therapy for portal hypertension.
Topics: Acute Disease; Adrenergic beta-Antagonists; Endoscopy, Gastrointestinal; Gastrointestinal Agents; Ga | 2001 |
Portal hypertension in schistosomiasis: pathophysiology and treatment.
Topics: Animals; Cricetinae; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1992 |
Prevention of first variceal bleeding: new prospects.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointesti | 1992 |
Balloon tamponade and vasoactive drugs in the control of acute variceal haemorrhage.
Topics: Antihypertensive Agents; Balloon Occlusion; Catheterization; Esophageal and Gastric Varices; Gastroi | 1992 |
Portal hypertensive gastropathy.
Topics: Animals; Diagnosis, Differential; Esophageal and Gastric Varices; Gastric Mucosa; Gastritis; Gastroi | 1992 |
Propranolol in variceal hemorrhage.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1992 |
[Beta-adrenergic antagonists and endoscopic sclerotherapy for the prevention of digestive hemorrhage].
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Endoscopy, Gastrointestinal; Gastrointestina | 1991 |
Portal hypertensive gastropathy.
Topics: Animals; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; | 1991 |
[Chemotherapy of portal hypertension].
Topics: Antihypertensive Agents; Drug Evaluation; Esophageal and Gastric Varices; Gastrointestinal Hemorrhag | 1991 |
Long-term pharmacologic therapy of portal hypertension.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension, Portal; M | 1990 |
Current status and future goals of the pharmacologic reduction of portal hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Hemodynamics; Humans; Hypertension, Portal; | 1990 |
Meta-analysis of value of propranolol in prevention of variceal haemorrhage.
Topics: Adrenergic beta-Antagonists; Chi-Square Distribution; Drug Evaluation; Esophageal and Gastric Varice | 1990 |
[Treatment of hemorrhage of esophageal varices].
Topics: Balloon Occlusion; Catheterization; Combined Modality Therapy; Esophageal and Gastric Varices; Gastr | 1990 |
New concepts of pathophysiology and treatment of portal hypertension.
Topics: Cardiology; Hemorrhage; Humans; Hypertension, Portal; Propranolol; Sclerotherapy; Varicose Veins; Va | 1990 |
[Beta blockaders and portal hypertension].
Topics: Adrenergic beta-Antagonists; Animals; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertensio | 1989 |
Safety of propranolol in portal hypertension. Conventional and long acting formulations.
Topics: Delayed-Action Preparations; Humans; Hypertension, Portal; Propranolol | 1989 |
[Pharmacological therapy of portal hypertension].
Topics: Acute Disease; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Esophageal an | 1985 |
Advances in managing variceal bleeding in portal hypertension.
Topics: Catheterization; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hemorrh | 1986 |
Drug therapy for portal hypertension.
Topics: Animals; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemo | 1986 |
Pharmacological therapy of portal hypertension.
Topics: Acute Disease; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hypertension, | 1986 |
The medical prevention of variceal bleeding.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1988 |
Management of the patient with hemorrhaging esophageal varices.
Topics: Airway Obstruction; Catheterization; Esophageal and Gastric Varices; Fluid Therapy; Gastrointestinal | 1986 |
Ideal treatment of portal hypertension in 1985.
Topics: Acute Disease; Clinical Trials as Topic; Double-Blind Method; Endoscopy; Esophageal and Gastric Vari | 1985 |
102 trials available for propranolol and Hypertension, Portal
| Article | Year |
|---|---|
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 2023 |
Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised c
Topics: China; Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Human | 2020 |
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
Topics: Adult; Antihypertensive Agents; Bacterial Translocation; Drug Therapy, Combination; Female; Gastroin | 2017 |
Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography.
Topics: Adrenergic beta-Antagonists; Aged; Aorta, Abdominal; Carbazoles; Carvedilol; Contrast Media; Female; | 2017 |
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atorvastatin; Disease Progression; Drug | 2018 |
PORTAL HYPERTENSION TREATMENT WITH CANDESARTAN PLUS PROPRANOLOL FOR NINE MONTHS RESTORES NORMAL PORTAL CIRCULATION HEMODYNAMIC PATTERN.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administration Schedule; Drug Ther | 2016 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Measurement of variceal pressure with a computerized endoscopic manometry: validation and effect of propranolol therapy in cirrhotic patients.
Topics: Adult; Antihypertensive Agents; Esophageal and Gastric Varices; Esophagoscopes; Esophagoscopy; Femal | 2013 |
Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Biomarkers; Chi-Square Distribution; Combined Mo | 2013 |
Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis.
Topics: Adult; China; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal He | 2013 |
Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Arteries; Blood Pressure; Bloo | 2014 |
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2014 |
Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Do | 2016 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrha | 2009 |
Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence.
Topics: Adult; Combined Modality Therapy; Endoscopy, Digestive System; Esophageal and Gastric Varices; Femal | 2009 |
Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Child; Child, Preschool; Esophageal and Gastric Vari | 2010 |
Carvedilol or propranolol in portal hypertension? A randomized comparison.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Fema | 2012 |
Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Female; Follow-Up Studies; | 2013 |
Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt.
Topics: Blood Pressure; Drug Combinations; Female; Heart Rate; Hemodynamics; Humans; Hypertension, Portal; L | 2002 |
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.
Topics: Adult; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Isosorbide Dinitrate; Male | 2002 |
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2002 |
[Effect of compound Salvia pill combined with propanolol on liver fibrosis and portal hypertension].
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up | 2002 |
Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2003 |
Long term effects of propranolol on portal pressure in cirrhotic patients.
Topics: Antihypertensive Agents; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemody | 2003 |
Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Esophageal and Gastric | 2003 |
Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Topics: Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparations; Esophageal and Gastric Varic | 2003 |
Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Flow Velocity; Captopril; D | 2003 |
Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2004 |
[Comparative effectiveness of different methods of diagnosis and correction of impaired portal circulation].
Topics: Antihypertensive Agents; Humans; Hypertension, Portal; Isosorbide Dinitrate; Laser Therapy; Liver Ci | 2004 |
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hu | 2005 |
Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Cause of Death; Epidemiologic Methods; Esophageal and Gastric Var | 2005 |
Functional status of beta-2-adrenoceptor in isolated membranes of mature erythrocytes from patients with cirrhosis and oesophageal varices.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alcohol Drinking; Cyclic A | 2006 |
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Topics: Adult; Aged; Antihypertensive Agents; Female; Hepatic Veins; Humans; Hypertension, Portal; Linear Mo | 2007 |
Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2008 |
Propranolol--a medical treatment for portal hypertension?
Topics: Administration, Oral; Cardiac Output; Clinical Trials as Topic; Esophageal and Gastric Varices; Gast | 1980 |
Propranolol in portal hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension, Portal; Male; Midd | 1981 |
Propranolol in decompensated alcoholic cirrhosis.
Topics: Heart; Humans; Hypertension, Portal; Liver Cirrhosis, Alcoholic; Male; Propranolol; Risk | 1982 |
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.
Topics: Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte | 1984 |
Propranolol and haemorrhage due to rupture of oesophageal varices.
Topics: Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hyper | 1984 |
Treatment of bleeding varices: controversy and opportunity.
Topics: Clinical Trials as Topic; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestina | 1984 |
Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension.
Topics: Cardiac Output; Female; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Meto | 1984 |
Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.
Topics: Adrenergic alpha-Antagonists; Aldosterone; Blood Pressure; Female; Furosemide; Glomerular Filtration | 1995 |
[Portal hypertension: value of combination of nitrate derivatives and beta blockers for better prevention?].
Topics: Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Portal; Isosorbide Dinitrate; | 1995 |
Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis.
Topics: Aged; Double-Blind Method; Female; Femoral Vein; Hepatic Veins; Humans; Hypertension, Portal; Liver | 1995 |
Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis, Al | 1993 |
Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy.
Topics: Double-Blind Method; Female; Gastric Mucosa; Gastrins; Gastrointestinal Hemorrhage; Humans; Hyperten | 1994 |
Prevention of rebleeding from oesophageal varices: two-year follow up of a prospective controlled trial of propranolol in addition to sclerotherapy.
Topics: Adolescent; Adult; Aged; Blood Pressure; Combined Modality Therapy; Esophageal and Gastric Varices; | 1994 |
Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis.
Topics: Adult; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hum | 1994 |
Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Topics: Aldosterone; Analysis of Variance; Body Water; Chi-Square Distribution; Dinoprostone; Drug Therapy, | 1994 |
Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics.
Topics: Delayed-Action Preparations; Double-Blind Method; Drug Monitoring; Esophageal and Gastric Varices; F | 1993 |
The effect of propranolol on portal perfusion in patients with alcoholic cirrhosis having distal splenorenal shunt.
Topics: Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis, Alcoholic; Male; Middle Aged; P | 1994 |
Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
Topics: Adult; Aged; Azygos Vein; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointesti | 1993 |
A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy.
Topics: Administration, Oral; Adolescent; Adult; Combined Modality Therapy; Double-Blind Method; Endoscopy; | 1993 |
Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.
Topics: Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Hemod | 1993 |
Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy.
Topics: Female; Gastric Mucosa; Hemodynamics; Humans; Hypertension, Portal; Injections, Intravenous; Laser-D | 1993 |
Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Blood Flow Velocity; Blood Pressure; Clonidine; Cro | 1995 |
The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Ascites; Atrial Natriuretic Factor; | 1996 |
Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study.
Topics: Adult; Aged; Antihypertensive Agents; Combined Modality Therapy; Esophageal and Gastric Varices; Fem | 1996 |
Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Portal | 1996 |
Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Ulcer Agents; Aspirin; Dinoprostone; Enprostil; Femal | 1995 |
Non-invasive variceal pressure measurements: validation and clinical implications.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Double-Blind Method; Esophageal | 1996 |
Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly.
Topics: Adrenergic beta-Antagonists; Humans; Hypertension, Portal; Isosorbide Dinitrate; Propranolol; Vasodi | 1997 |
Assessment of effects of propranolol on portal hemodynamics in cirrhosis by duplex ultrasonography.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Cross-Over Studies; Hemodynamics; Humans | 1998 |
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Drug Therapy, Combination; Female; | 1998 |
Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Endoscopy; Esophageal and Gastric Varices; Female; Gastrointesti | 1999 |
Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastr | 1999 |
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Esophageal and Gastric Varices; Female | 1999 |
Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Area Under Curve; Female; Hemodynamics; Humans | 1999 |
A comparative study of the elective treatment of variceal hemorrhage with beta-blockers, transendoscopic sclerotherapy, and surgery: a prospective, controlled, and randomized trial during 10 years.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Endoscopy; Female; Hemorrhage; Humans; Hyperte | 2000 |
Effects of ondansetron on portal hemodynamics in liver cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Double-Blind Method; Female; Hemodynamics; Humans; Hyperte | 2000 |
The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial.
Topics: Adult; Aged; Combined Modality Therapy; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; | 2001 |
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Glomerular | 2001 |
Total effective vascular compliance in patients with cirrhosis. Effects of propranolol.
Topics: Compliance; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; | 2002 |
Propranolol ameliorates thrombocytopenia in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Age | 2002 |
Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Carbazole | 2002 |
Echo-Doppler evaluation of acute flow changes in portal hypertensive patients: flow velocity as a reliable parameter.
Topics: Aged; Double-Blind Method; Echocardiography, Doppler; Female; Hemodynamics; Humans; Hypertension, Po | 1992 |
[Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound].
Topics: Adult; Aged; Blood Flow Velocity; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; L | 1992 |
Effects of beta-adrenoreceptor antagonists on cerebral blood flow of cirrhotic patients with portal hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Cerebral Cortex; Cerebrovascular | 1991 |
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.
Topics: Actuarial Analysis; Acute Disease; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up | 1991 |
[Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy].
Topics: Actuarial Analysis; Adult; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Foll | 1991 |
[Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Antihypertensive Agents; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isosorb | 1991 |
Long-term pharmacologic therapy of portal hypertension.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension, Portal; M | 1990 |
Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
Topics: Aged; Drug Therapy, Combination; Female; Hemodynamics; Hepatic Veins; Humans; Hypertension, Portal; | 1991 |
Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.
Topics: Blood Pressure; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorr | 1991 |
Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Double-Blind Method; Esophageal and Gastr | 1991 |
Portal hypertension therapy with oral propranolol. A short-term study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Humans; Hypertension, Portal; | 1990 |
Efficacy of oral propranolol and injection sclerotherapy in the long-term management of variceal bleeding.
Topics: Administration, Oral; Adult; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hu | 1990 |
Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Vari | 1989 |
Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Exercise; Heart Rate; Humans; Hypertension | 1989 |
A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding.
Topics: Aged; Female; Gastrointestinal Hemorrhage; Hepatitis B Surface Antigens; Humans; Hypertension, Porta | 1989 |
[Propranolol in the prevention of digestive bleeding in cirrhotic patients].
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Ga | 1989 |
[Pharmacological therapy of portal hypertension].
Topics: Acute Disease; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Esophageal an | 1985 |
Drug therapy for portal hypertension.
Topics: Animals; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemo | 1986 |
Comparative haemodynamic effects of betaxolol and propranolol in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Female; Humans; Hypertension, Portal; Liver Circulati | 1988 |
The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.
Topics: Adult; Aged; Double-Blind Method; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Hy | 1988 |
Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial.
Topics: Adult; Clinical Trials as Topic; Endoscopy; Esophageal and Gastric Varices; Female; Follow-Up Studie | 1988 |
Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol.
Topics: Ammonia; Arteries; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Prop | 1988 |
A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension.
Topics: Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis | 1986 |
[Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients].
Topics: Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointe | 1987 |
Ideal treatment of portal hypertension in 1985.
Topics: Acute Disease; Clinical Trials as Topic; Double-Blind Method; Endoscopy; Esophageal and Gastric Vari | 1985 |
183 other studies available for propranolol and Hypertension, Portal
| Article | Year |
|---|---|
[CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis].
Topics: Adrenergic Antagonists; Cytochrome P-450 CYP2D6; Hemodynamics; Humans; Hypertension, Portal; Liver C | 2022 |
Effect of beta-blockers on multiple haemodynamics in cirrhosis: A cross-over study by MR-imaging and hepatic vein catheterization.
Topics: Adrenergic beta-Antagonists; Ascites; Catheterization; Cross-Over Studies; Hemodynamics; Hepatic Vei | 2023 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
Diagnosis and management of extrahepatic oesophageal variceal bleed in children in a low resourced setting.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Esophageal and Gastric Varices; Female; | 2020 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Pregnancy in a patient with portal hypertension secondary to liver cirrhosis.
Topics: Adult; Antihypertensive Agents; Cardiotocography; Esophageal and Gastric Varices; Female; Gastrointe | 2018 |
Participation of hepatic α/β-adrenoceptors and AT1 receptors in glucose release and portal hypertensive response induced by adrenaline or angiotensin II.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonis | 2018 |
Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival.
Topics: Adult; Aged; Antihypertensive Agents; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gas | 2019 |
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Female; Humans; Hypertension, Portal; Infusions, Intr | 2019 |
Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Decision Support Techniques; Esophageal and Gastric Varice | 2019 |
Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Disease Progression; Elasticity Imaging Technique | 2019 |
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Hemodynam | 2013 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted | 2012 |
Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Determination; D | 2013 |
Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
Topics: Adrenergic beta-Antagonists; Animals; Cholecalciferol; Disease Models, Animal; Drug Therapy, Combina | 2015 |
Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension.
Topics: Adolescent; Antihypertensive Agents; Ascites; Blood Pressure; Cardiomyopathies; Case-Control Studies | 2015 |
Extrahepatic portal vein obstruction in Egyptian children.
Topics: Child; Child, Preschool; Cohort Studies; Diagnosis, Differential; Egypt; Esophageal and Gastric Vari | 2015 |
β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Biopsy; Child; Child, Preschool; Female; Humans; Hypersplen | 2015 |
Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?
Topics: Adrenergic beta-Antagonists; Female; Humans; Hypersplenism; Hypertension, Portal; Male; Propranolol | 2015 |
β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Case-Control Studies; Esophageal and Gastric V | 2015 |
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Topics: Animals; Blood Pressure; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Metformin; Portal Vein; | 2015 |
Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Bacterial Trans | 2016 |
Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.
Topics: Adrenergic beta-Antagonists; Ascites; Child; Esophageal and Gastric Varices; Hepatorenal Syndrome; H | 2016 |
Propranolol improves endothelial dysfunction in advanced cirrhosis: the 'endothelial exhaustion' hypothesis.
Topics: Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol | 2016 |
The anti-inflammatory role of propranolol in cirrhosis: Preventing the inflammatory exhaustion?
Topics: Anti-Inflammatory Agents; Esophageal and Gastric Varices; Humans; Hypertension, Portal; Liver Cirrho | 2017 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats.
Topics: Animals; Carbon Tetrachloride; Esophageal and Gastric Varices; Hypertension, Portal; Liver Cirrhosis | 2009 |
Combined use of propranolol and nifedipine offers better effects on portal vein nonuniform remodeling in carbon tetrachloride (CCl(4))-induced portal hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Carbon Tetrachloride; Drug Combinati | 2009 |
Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Cohort Studies; Female; Hemorrhage; Humans; Hypertension, Portal; | 2009 |
Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Endosonography; Esophageal and Gastric Varices; Esophag | 2009 |
Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Gastric Mucosa; Hypertension, Portal; Liver Cirrhosis, Experimental | 2009 |
Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.
Topics: Animals; Cyclic AMP; Cyclic GMP-Dependent Protein Kinases; Hepatic Stellate Cells; Humans; Hypertens | 2009 |
The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Case-Control Studies; Female; Hemodynamics | 2010 |
Non-invasive measurement of cardiac output by Finometer in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiac Output; Diagnostic Techniques, Cardiovascular; Equ | 2010 |
Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Humans; Hypertension, Portal; Liver Cirrhos | 2011 |
Refractory iron-deficiency anaemia in a child with portal cavernoma.
Topics: Anemia, Iron-Deficiency; Antihypertensive Agents; Child; Hemangioma, Cavernous; Humans; Hypertension | 2011 |
An uncommon cause of portal hypertension: schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Antihypertensive Agents; Hepatomegaly; Humans; Hypertension, Portal; | 2011 |
[Beta-blockers in portal hypertension: Unexpected limitations!].
Topics: Adrenergic beta-Antagonists; Cause of Death; Esophageal and Gastric Varices; Esophagoscopy; Gastroin | 2011 |
The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study).
Topics: Adult; Area Under Curve; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Function Tests; Male; | 2011 |
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists.
Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator | 2011 |
Important details to be clarified about the effect of rectal ozone on the portal vein oxygenation.
Topics: Humans; Hypertension, Portal; Liver Cirrhosis; Male; Ozone; Portal Vein; Propranolol; Vasodilator Ag | 2011 |
Propranolol modulates the collateral vascular responsiveness to vasopressin via a G(α)-mediated pathway in portal hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arginine Vasopressin; Collateral Circ | 2011 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
Topics: Animals; Antihypertensive Agents; Benzenesulfonates; Drug Therapy, Combination; Hypertension, Portal | 2012 |
Insulin resistance in patients with cirrhosis and portal hypertension.
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Portal; Insulin Resistance; Liver; Liver Ci | 2012 |
Portal hypertension in children.
Topics: Child; Endoscopy, Digestive System; Esophageal and Gastric Varices; Humans; Hypertension, Portal; Li | 2012 |
Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Topics: Animals; Antiparkinson Agents; Bile Ducts; Blood Pressure; Carbidopa; Carbon Tetrachloride; Disease | 2012 |
Endoscopic and pharmacological secondary prophylaxis in children and adolescents with esophageal varices.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Endoscopy, Gastrointestinal; Esoph | 2013 |
Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Body Weight; Carbon Tetrachloride; Ca | 2013 |
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis.
Topics: Adrenergic beta-Antagonists; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gast | 2002 |
Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Transjugular intrahepatic portosystemic shunt.
Topics: Adult; Antihypertensive Agents; Cardiac Output; Heart Rate; Humans; Hypertension, Portal; Middle Age | 2003 |
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F | 2003 |
"A la carte" treatment of portal hypertension or just "hors d'oeuvres".
Topics: Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertension, Portal; Isosorbide Dinitrate; Losar | 2003 |
Does losartan work after all?
Topics: Antihypertensive Agents; Humans; Hypertension, Portal; Liver Cirrhosis; Losartan; Propranolol; Rando | 2003 |
Long-term outcome after sclerotherapy with or without a beta-blocker for variceal bleeding in children.
Topics: Antihypertensive Agents; Child; Child, Preschool; Combined Modality Therapy; Esophageal and Gastric | 2003 |
Ectopic intestinal varices as a rare cause of lower gastrointestinal haemorrhage.
Topics: Antihypertensive Agents; Endoscopy, Digestive System; Esophageal and Gastric Varices; Gastrointestin | 2003 |
Reversal of portal hypertension in a patient with primary biliary cirrhosis: disappearance of esophageal varices and thrombocytopenia.
Topics: Biopsy, Needle; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Follow-Up Studies | 2004 |
[Variceal hemorrhage: primary and secondary prophylaxis].
Topics: Adrenergic beta-Antagonists; Algorithms; Esophageal and Gastric Varices; Esophagoscopy; Gastrointest | 2004 |
[Cirrhotic cardiomyopathy: prolonged QTc-interval and dyssynchronic electrical and mechanical systole in cirrhosis].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomyopathies; Electrocardiography; Female; Heart; Hemo | 2004 |
Optimal use of propranolol in portal hypertension.
Topics: Antihypertensive Agents; Drug Administration Schedule; Humans; Hypertension, Portal; Propranolol | 2005 |
[Pharmacological therapy of portal hypertension--focused on Korean data].
Topics: Adrenergic beta-Antagonists; Hepatic Veins; Humans; Hypertension, Portal; Korea; Liver Cirrhosis; Pr | 2005 |
The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Flow Velocity; Drug Therapy, Combination; Female; Follow-U | 2005 |
Effects of norepinephrine and acetylcholine on portal-systemic collaterals of common bile duct-ligated cirrhotic rat.
Topics: Acetylcholine; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertens | 2005 |
Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.
Topics: Adult; Aged; Female; Genotype; Haplotypes; Heart Rate; Hepatic Veins; Humans; Hypertension, Portal; | 2006 |
Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension.
Topics: Animals; Blood Pressure; Compliance; Hypertension, Portal; Male; Portal Vein; Propranolol; Rats; Rat | 2006 |
[Hemorrhage due to peristomal ectopic varices: an infrequent complication of portal hypertension].
Topics: Cecal Neoplasms; Colonic Neoplasms; Diabetes Mellitus, Type 2; Duodenal Ulcer; Gastrointestinal Hemo | 2006 |
Chronic stomal variceal bleeding after colonic surgery in patients with portal hypertension: efficacy of beta-blocking agents?
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Colostomy; Gastrointestinal Hemorrhage; Humans; | 2006 |
[The effect of angiotensin II type 1 receptor blocker valsartan in rats with portal hypertensive gastropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Gastric Mucosa; Hypertension, Portal; Male; Propra | 2006 |
Portal systemic collateral development: is it a trophic adaptation mechanism to hepatic deprivation?
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Collateral | 2006 |
A patient with diabetes mellitus and recurrent peristomal bleeding.
Topics: Aged; Antihypertensive Agents; Colostomy; Diabetes Mellitus, Type 2; Diagnosis, Differential; Electr | 2006 |
The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol.
Topics: Antihypertensive Agents; Bacterial Infections; Esophageal and Gastric Varices; Gastrointestinal Hemo | 2006 |
Zhi-fuzi, a cardiotonic Chinese herb, a new medical treatment choice for portal hypertension?
Topics: Aconitum; Animals; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Drug Evaluation, Prec | 2007 |
Management practices for gastrointestinal hemorrhage related to portal hypertension in cirrhotic patients: evaluation of the impact of the Paris consensus workshop.
Topics: Adrenergic beta-Antagonists; Antibiotic Prophylaxis; Drug Utilization; France; Gastrointestinal Hemo | 2007 |
Propranolol and portal hypertension in cirrhosis.
Topics: Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol | 1980 |
Propranolol for portal hypertension.
Topics: Humans; Hypertension, Portal; Propranolol | 1981 |
Risk of hepatic encephalopathy in patients taking propranolol for portal hypertension.
Topics: Hepatic Encephalopathy; Humans; Hypertension, Portal; Propranolol; Risk | 1982 |
Portal hypertension, propranolol, and hepatic encephalopathy.
Topics: Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis; Portacaval Shunt, Surgical; P | 1982 |
Propranolol increases arterial ammonia in liver cirrhosis.
Topics: Adult; Aged; Ammonia; Arteries; Chronic Disease; Fatty Liver, Alcoholic; Female; Humans; Hypertensio | 1982 |
Drug therapy of portal hypertension due to cirrhosis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertension, Por | 1982 |
[Beta-blockers and portal hypertension].
Topics: Adrenergic beta-Antagonists; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrho | 1984 |
Drug therapy of portal hypertension and oesophageal varices.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1984 |
Medical treatment of portal hypertension and oesophageal varices.
Topics: Animals; Humans; Hypertension, Portal; Liver Circulation; Propranolol; Rats | 1983 |
Effect of propranolol and sclerotherapy in bleeding esophageal varices. A case report.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Huma | 1984 |
[Liver bypass model following portosystemic anastomoses in children with portal hypertension].
Topics: Adult; Blood Glucose; Child; Child, Preschool; Humans; Hypertension, Portal; Kinetics; Phenylalanine | 1983 |
Effect of intravenous propranolol on portal hypertension.
Topics: Adult; Female; Humans; Hypertension, Portal; Injections, Intravenous; Male; Middle Aged; Propranolol | 1984 |
Propranolol: its role in the management of portal hypertension. The ACG Committee on FDA related matters.
Topics: Esophageal and Gastric Varices; Humans; Hypertension, Portal; Liver Cirrhosis, Alcoholic; Propranolo | 1983 |
[Propranolol treatment of hemorrhage due to portal hypertension].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranolol | 1981 |
[Medical treatment of hemorrhage in portal hypertension of the cirrhotic patient using propanolol].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol; Recurrence | 1982 |
Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats.
Topics: Animals; Blood Pressure; Cardiac Output; Heart Rate; Hypertension, Portal; Liver Circulation; Male; | 1982 |
[Physiopathological bases of the medical treatment of portal hypertension].
Topics: Hemodynamics; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Propranolol; Vascula | 1982 |
Effects of propranolol on intestinal microcirculation of normal and portal hypertensive rats.
Topics: Animals; Drug Administration Routes; Hemodynamics; Hypertension, Portal; Intestines; Male; Microcirc | 1995 |
[Study of gastric mucosal lesion in portal hypertension].
Topics: Antihypertensive Agents; Esophageal and Gastric Varices; Gastric Mucosa; Gastroscopy; Humans; Hypert | 1995 |
IgA nephropathy associated with portal hypertension in liver cirrhosis due to non-alcoholic and non-A, non-B, non-C hepatitis.
Topics: Aged; Female; Glomerulonephritis, IGA; Hepatitis; Humans; Hypertension, Portal; Kidney Glomerulus; L | 1994 |
Hemodynamic responses to selective blockade of beta 2- and beta 1-adrenoceptors in conscious rats with cirrhosis.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Drug Combinations; Hemodynamics; Hypertension, Porta | 1994 |
Shunt surgery and beta-blockers.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Humans; Hypertension, Portal; Liver Cir | 1994 |
Effects of beta-adrenoceptor antagonists on portal vein hypertension and ethanol-induced gastric mucosal damage in rats.
Topics: Adrenergic beta-Antagonists; Animals; Ethanol; Gastric Mucosa; Hemodynamics; Hypertension, Portal; L | 1994 |
[Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II].
Topics: Adult; Aged; Blood Pressure; Collateral Circulation; Esophageal and Gastric Varices; Female; Gastroi | 1994 |
[Addition of ritanserin to the treatment with propranolol in cirrhotic patients: effects on portal pressure].
Topics: Adult; Aged; Drug Therapy, Combination; Humans; Hypertension, Portal; Middle Aged; Propranolol; Rita | 1994 |
Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Blood Circulation; Hemodynamics; Hypertension, Portal; Male; P | 1993 |
Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats.
Topics: Aging; Animals; Blood Pressure; Cardiovascular System; Dose-Response Relationship, Drug; Heart Rate; | 1993 |
Bleeding varices due to portal hypertension in sarcoidosis. Favorable effect of propranolol and prednisone.
Topics: Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hype | 1993 |
Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol.
Topics: Animals; Blood Pressure; Carbon Dioxide; Heart Rate; Hemodynamics; Hydrogen-Ion Concentration; Hyper | 1993 |
Propranolol in the control of haemorrhage from varices around a urostomy.
Topics: Aged; Anastomosis, Surgical; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 1993 |
Portal hypertension revisited.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Portasyst | 1995 |
Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Drug Synergism; Drug Therapy, Combination; Female; Hemodynamics; Humans | 1996 |
Haemodynamic effects of combined treatment with molsidomine and propranolol on portal hypertension in conscious and unrestrained cirrhotic rats.
Topics: Animals; Drug Therapy, Combination; Hemodynamics; Hypertension, Portal; Liver Cirrhosis, Experimenta | 1996 |
Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Blood Flow Velocity; Esophageal and Gastric Varices; Hemodynamic | 1997 |
Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.
Topics: Animals; Antihypertensive Agents; Cholestasis; Drug Evaluation, Preclinical; Drug Therapy, Combinati | 1997 |
Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats.
Topics: Animals; Hemodynamics; Hypertension, Portal; Intubation, Gastrointestinal; Mesenteric Artery, Superi | 1997 |
Haemodynamic effects of octreotide in portal hypertensive rats receiving propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Drug Interactions; Heart Rate; Hemodynamics; H | 1997 |
Hemodynamic effects of chronic tetrandrine and propranolol administration on portal hypertensive rats.
Topics: Administration, Oral; Alkaloids; Analysis of Variance; Animals; Antihypertensive Agents; Benzylisoqu | 1997 |
Long-term treatment of bleeding caused by portal hypertension in children.
Topics: Administration, Oral; Adult; Child; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal | 1997 |
Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Drug Therapy, Combination; Hemodynamics; Hormones; Hypertensio | 1998 |
Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol.
Topics: Adult; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Female; Hemodynamics; Hum | 1998 |
Clinical vs haemodynamic response to drugs in portal hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Esophageal and Gastric Varices; Female; Follow-Up Studi | 1998 |
Noninvasive endoscopic determination of intravariceal pressure in patients with portal hypertension: clinical experience with a new balloon technique.
Topics: Adult; Aged; Antihypertensive Agents; Case-Control Studies; Endoscopy, Digestive System; Equipment D | 1998 |
Increased angiogenesis in portal hypertensive rats: role of nitric oxide.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Disease Models, Animal; Hypertension, Portal; Ima | 1999 |
[Evaluation of propranolol response by catheterization and Doppler ultrasonography in patients with cirrhosis].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Catheterization; Female; Humans; Hypertension, Portal; Liv | 1998 |
Propranolol and portal hypertension: should kids be on the block?
Topics: Antihypertensive Agents; Child; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; | 1999 |
An advance in the treatment of portal hypertension?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 2000 |
Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aorta; Atenolol; Constriction, Pathol | 2000 |
Betablocker, hepatic functions and confusion.
Topics: Adrenergic beta-Antagonists; Confusion; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Functio | 1999 |
Re: Orozco et al. A comparative study of the elective treatment of variceal hemorrhage with beta-blockers, transendoscopic sclerotherapy and surgery. A prospective, controlled, and randomized trial during 10 years. Ann Surg 2000; 232:216-9.
Topics: Adrenergic beta-Antagonists; Hemorrhage; Humans; Hypertension, Portal; Propranolol; Sclerotherapy; V | 2001 |
Effect of beta-adrenergic blockade on elevated arterial compliance and low systemic vascular resistance in cirrhosis.
Topics: Adrenergic beta-Antagonists; Female; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosi | 2001 |
Systemic and splanchnic hemodynamics following hemorrhage and volume restitution with Haemaccel in portal hypertensive rats: the effect of propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Heart | 2001 |
Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Losartan; Male; Prop | 2002 |
[Measurement of liver circulation by means of an ultrasonic Doppler flow measuring device].
Topics: Animals; Blood Flow Velocity; Dogs; Doppler Effect; Hepatic Artery; Hypertension, Portal; Ligation; | 1977 |
[Colostomy-induced varices in portal hypertension].
Topics: Aged; Colon; Colostomy; Female; Humans; Hypertension, Portal; Male; Middle Aged; Prognosis; Proprano | 1992 |
Propranolol for portal hypertensive gastropathy: another virtue of beta-blockade?
Topics: Adrenergic beta-Antagonists; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrho | 1992 |
Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Female; Hemodynamics; Humans; Hypertension | 1992 |
[Duplex ultrasound studies of the portal vein system. Hemodynamic changes in liver cirrhosis].
Topics: Blood Flow Velocity; Humans; Hypertension, Portal; Liver Cirrhosis; Portal Vein; Propranolol; Ultras | 1992 |
Portal pressure response to propranolol in portal hypertension.
Topics: Blood Pressure; Humans; Hypertension, Portal; Portal Vein; Propranolol | 1992 |
Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats.
Topics: Animals; Consciousness; Drug Therapy, Combination; Hemodynamics; Hypertension, Portal; Liver Cirrhos | 1992 |
[Adrenergic beta blockade in liver cirrhosis with portal hypertension? Doppler ultrasound measurement of the short-term effect of propranolol on the portal system].
Topics: Blood Flow Velocity; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1992 |
Beta-blockers in portal hypertension: variation on a theme.
Topics: Acute Disease; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranolol | 1992 |
Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats.
Topics: Animals; Collateral Circulation; Constriction, Pathologic; Hemodynamics; Hypertension, Portal; Male; | 1991 |
[Propranolol in portal hypertensive gastropathy].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol; Stomach Dis | 1991 |
[Pharmacological lowering of portal pressure in normal rats and in experimental liver cirrhosis].
Topics: Acute Disease; Animals; Blood Pressure; Canrenoic Acid; Heart Rate; Hypertension, Portal; Liver Cirr | 1991 |
[Sclerosing treatment of esophageal varices].
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; L | 1991 |
Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.
Topics: Animals; Blood Pressure; Chronic Disease; Collagen; Granuloma; Heart Rate; Hemodynamics; Hepatic Art | 1991 |
The influence of propanolol on portosystemic shunting.
Topics: Animals; Blood Circulation; Hypertension, Portal; Mice; Mice, Inbred C3H; Portal System; Propranolol | 1991 |
[Prevention of gastrointestinal hemorrhage caused by portal thrombosis with propranolol. Report of a case with an 8 year follow-up].
Topics: Aged; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Male; Portal Vei | 1990 |
Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Topics: Aged; Blood Pressure; Female; Hemodynamics; Humans; Hypertension, Portal; Isosorbide Dinitrate; Live | 1990 |
Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis.
Topics: Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Oxygen; Prop | 1990 |
Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats.
Topics: Animals; Disease Models, Animal; Drug Interactions; Gastric Acid; Gastric Mucosa; Hypertension, Port | 1990 |
Effects of propranolol and nitroglycerin on portal pressure and the mechanism of their reducing portal pressure.
Topics: Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, Portal; Liver Circulation; Nitroglyce | 1989 |
Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
Topics: Adult; Collateral Circulation; Female; Gastrointestinal Hemorrhage; Heart Rate; Hemodynamics; Hepati | 1989 |
[The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Ascites; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hy | 1989 |
Portasystemic shunt fraction quantification using transrectal administration of iodine-123 iodoamphetamine in dogs with chronic bile duct ligation and after propranolol administration.
Topics: Amphetamines; Animals; Bile Ducts; Dogs; Hemodynamics; Hypertension, Portal; Iodine Radioisotopes; L | 1989 |
Treatment options in portal hypertension: Does propranolol have a role? Proceedings of a satellite symposium of the XIII International Congress of Gastroenterology and the VI European Congress of Digestive Endoscopy. Rome, 9 September 1988.
Topics: Humans; Hypertension, Portal; Propranolol | 1989 |
Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiac Output; Heart Rate; Hemodyna | 1985 |
Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect.
Topics: Drug Synergism; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, Portal; Ketanserin; L | 1989 |
Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Hear | 1989 |
Endoscopic, portographic, and hemodynamic evaluation of prolonged propranolol administration in pigs with experimental portal hypertension and esophageal varices.
Topics: Animals; Esophageal and Gastric Varices; Esophagoscopy; Hemodynamics; Hypertension, Portal; Liver; M | 1989 |
Haemodynamic rebound phenomena after abrupt cessation of propranolol therapy in portal hypertensive rats.
Topics: Animals; Depression, Chemical; Dose-Response Relationship, Drug; Heart Rate; Hemodynamics; Hypertens | 1986 |
Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis.
Topics: Azygos Vein; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; | 1987 |
Rheohepatogram as a parameter in assessing immediate effects of propranolol on portal hypertension.
Topics: Adult; Female; Heart Rate; Humans; Hypertension, Portal; Liver Circulation; Male; Middle Aged; Pleth | 1986 |
[The effects of propranolol or nitroglycerin on azygos blood flow in patients with portal hypertension].
Topics: Azygos Vein; Humans; Hypertension, Portal; Nitroglycerin; Propranolol; Regional Blood Flow | 1986 |
Effects of propranolol and nitroglycerin on cephalad collateral venous flow in patients with cirrhosis: evaluation using transesophageal real-time two-dimensional Doppler echography.
Topics: Aged; Aorta; Azygos Vein; Blood Flow Velocity; Collateral Circulation; Color; Female; Humans; Hypert | 1988 |
[Hemorrhage caused by portal hypertension at the level of a colostomy. Efficacy of propranolol?].
Topics: Colostomy; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Middle Aged; Propranol | 1988 |
Persistent hemorrhagic gastritis in a patient with portal hypertension and esophagogastric varices: the role of portal decompressive surgery.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastritis; Gastrointestinal Hemorrhage; Humans; Hypert | 1988 |
[Effect of propranolol on intrahepatic portal hypertension in the rat].
Topics: Animals; Blood Pressure; Carbon Tetrachloride Poisoning; Female; Heart Rate; Hypertension, Portal; L | 1987 |
[Effects of sotalol on blocked suprahepatic pressure in cirrhotic patients].
Topics: Aged; Blood Pressure; Cardiac Output; Cough; Female; Hepatic Veins; Humans; Hypertension, Portal; Li | 1987 |
[Prevention of recurrent hemorrhage due to portal hypertension].
Topics: Double-Blind Method; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhage; Hum | 1986 |
[Behavior of blood ammonia, insulin, glucagon, renin and prolactin during propranolol therapy in cirrhosis patients with portal hypertension].
Topics: Adult; Aged; Ammonia; Dose-Response Relationship, Drug; Drug Evaluation; Female; Glucagon; Humans; H | 1986 |
Effects of propranolol and sucralfate on ethanol-induced gastric mucosal damage in chronic portal hypertensive rats.
Topics: Animals; Dose-Response Relationship, Drug; Ethanol; Gastric Mucosa; Hypertension, Portal; Male; Prop | 1987 |
[Medical therapy of portal hypertension].
Topics: Atenolol; Cardiac Output; Humans; Hypertension, Portal; Metoprolol; Propranolol | 1986 |
[Portal hypertension in children. Therapeutic approach in cases of failure of a portosystemic shunt].
Topics: Adolescent; Child; Child, Preschool; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Esophagea | 1986 |
Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.
Topics: Adult; Aged; Cardiac Output; Heart Rate; Hemodynamics; Hepatitis B; Hepatitis B Surface Antigens; Hu | 1986 |
[Indications for surgery in portal hypertension from the internist's viewpoint].
Topics: Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; | 1985 |
Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol.
Topics: Azygos Vein; Collateral Circulation; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hu | 1985 |
Effects of propranolol on portal hemodynamics in patients with chronic liver disease.
Topics: Adult; Aged; Esophageal and Gastric Varices; Female; Hemodynamics; Humans; Hypertension, Portal; Mal | 1985 |
[Rheohepatographic assessment of the therapeutic effects of propranolol on portal hypertension].
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; | 1985 |
Propranolol reduces ethanol-induced gastric mucosal damage in portal hypertensive rats.
Topics: Animals; Blood Pressure; Ethanol; Gastric Mucosa; Hypertension, Portal; Male; Necrosis; Portal Syste | 1986 |
Pharmacology of propranolol in patients with cirrhosis and portal hypertension.
Topics: Aged; Female; Heart Rate; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Proprano | 1985 |
Effect of propranolol on renal blood flow in portal hypertensive rats.
Topics: Animals; Hypertension, Portal; Propranolol; Rats; Renal Circulation | 1985 |
Propranolol therapy for portal hypertension in children.
Topics: Adolescent; Anemia; Blood Pressure; Cardiac Output; Child; Child, Preschool; Female; Humans; Hyperte | 1985 |
Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal vein pressure.
Topics: Blood Pressure; Blood Pressure Determination; Heart Rate; Humans; Hypertension, Portal; Liver Diseas | 1985 |
Variceal bleeding from an ileostomy stoma.
Topics: Hemorrhage; Humans; Hypertension, Portal; Ileostomy; Ileum; Ligation; Male; Middle Aged; Propranolol | 1985 |
Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
Topics: Adult; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; | 1985 |
Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats.
Topics: Animals; Blood Pressure; Cardiac Output; Hepatic Artery; Hypertension, Portal; Male; Portal Vein; Pr | 1985 |
[The effect of propranolol on portal hypertension in patients with varices after esophageal transection].
Topics: Esophageal and Gastric Varices; Esophagus; Hemodynamics; Humans; Hypertension, Portal; Postoperative | 1985 |
[Chronotropic effect of a combined injection of calcium ions and beta-receptor blockaders].
Topics: Adrenergic beta-Antagonists; Blood Pressure Determination; Calcium; Drug Synergism; Electrocardiogra | 1971 |